<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1301256587
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BESPONSA 0.9 mg Vial
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INOTUZUMAB OZOGAMICIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.9
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        40383.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="WYETH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            WYETH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient in BESPONSA is inotuzumab ozogamicin. This belongs to a group of medicines that target cancer cells. These medicines are called antineoplastic agents.</p><p>&nbsp;</p><p>BESPONSA is used to treat adults with acute lymphoblastic leukaemia. Acute lymphoblastic leukaemia is a cancer of blood where you have too many white blood cells.</p><p>&nbsp;</p><p>&nbsp;</p><p>BESPONSA acts by attaching to cells with a protein called CD22. Lymphoblastic leukaemia cells have this protein. Once attached to the lymphoblastic leukaemia cells, the medicine delivers a substance into the cells that interferes with the cells&rsquo; DNA and eventually kills them.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use BESPONSA if you:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to inotuzumab ozogamicin or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have previously had severe venoocclusive disease (a condition in which the blood vessels in the liver become damaged and blocked by blood clots) which was confirmed or have ongoing venoocclusive disease.</p><ul><li>have serious ongoing liver disease, e.g., cirrhosis (a condition in which the liver does not function properly due to long-term damage), nodular regenerative hyperplasia (a condition with signs and symptoms of portal hypertension that can be caused by chronic use of medicines), active hepatitis (a disease characterised by inflammation of the liver).</li></ul><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions </strong></p><p>&nbsp;</p><p>Talk to your doctor, pharmacist or nurse before using BESPONSA if you:</p><p>&nbsp;</p><ul><li>have a history of liver problems or liver diseases or if you have signs and symptoms of a serious condition called hepatic venoocclusive disease, a condition in which the blood vessels in the liver become damaged and blocked by blood clots. Venoocclusive disease may be fatal and is associated with rapid weight gain, pain in the upper right side of your abdomen (belly), increase in the size of the liver, build-up of fluid causing abdominal swelling, and blood tests showing increases in bilirubin and/or liver enzymes (that may result in yellowing of the skin or eyes). This condition may occur during treatment with BESPONSA or after subsequent treatment with a stem cell transplant. A stem cell transplant is a procedure to transplant another person&rsquo;s stem cells (cells which develop into new blood cells) into your bloodstream. This procedure may take place if your disease responds completely to treatment.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have signs or symptoms of a low number of blood cells known as neutrophils (sometimes accompanied with fever), red blood cells, white blood cells, lymphocytes, or a low number of blood components known as platelets; these signs and symptoms include developing an infection or fever or bruising easily, or getting frequent nose bleeds.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have signs and symptoms of an infusion related reaction, such as fever and chills or breathing problems during or shortly after the BESPONSA infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have signs and symptoms of tumour lysis syndrome, which may be associated with symptoms in the stomach and intestines (for example, nausea, vomiting, diarrhoea), heart (for example, changes in the rhythm), kidney (for example, decreased urine, blood in urine), and nerves and muscles (for example, muscular spasms, weakness, cramps), during or shortly after the BESPONSA infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of, or tendency to have, QT interval prolongation (a change in electrical activity of the heart that can cause serious irregular heart rhythms), are taking medicines that are known to prolong QT interval, and/or have abnormal electrolyte (e.g., calcium, magnesium, potassium) levels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have elevations in amylase or lipase enzymes that may be a sign of problems with your pancreas or liver and gallbladder or bile ducts.</p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor, pharmacist or nurse immediately </strong>if you became pregnant during the period of treatment with BESPONSA and for up to 8 months after finishing treatment.</p><p>&nbsp;</p><p>Your doctor will take regular blood tests to monitor your blood counts during treatment with BESPONSA. See also section 4.</p><p>&nbsp;</p><p>During treatment, especially in the first few days after starting treatment, your white blood cell count may be severely lowered (neutropenia), which may be accompanied by fever (febrile neutropenia).</p><p>&nbsp;</p><p>During treatment, especially in the first few days after starting treatment, you may have raised liver enzymes. Your doctor will take regular blood tests to monitor your liver enzymes during treatment with BESPONSA.</p><p>&nbsp;</p><p>Treatment with BESPONSA may prolong QT interval (a change in electrical activity of the heart that can cause serious irregular heart rhythms). Your doctor will take an electrocardiogram (ECG) and blood tests to measure electrolytes (e.g., calcium, magnesium, potassium) before the first dose of BESPONSA and repeat these tests during treatment. See also section 4.</p><p>&nbsp;</p><p>Your doctor will also monitor for signs and symptoms of tumour lysis syndrome after you receive BESPONSA. See also section 4.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p>BESPONSA should not to be used in children and adolescents under 18 years of age because no data are available in this population.</p><p>&nbsp;</p><p><strong>Other medicines and BESPONSA</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><strong>&nbsp;</strong></p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before taking this medicine.</p><p><strong>&nbsp;</strong></p><p><u>Contraception </u></p><p>&nbsp;</p><p>You must avoid becoming pregnant or fathering a child. Women must use effective contraception during treatment and for at least 8&nbsp;months after the last dose of treatment. Men must use effective contraception during treatment and for at least 5&nbsp;months after the last dose of treatment.</p><p><strong>&nbsp;</strong></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>The effects of BESPONSA in pregnant women are not known, but based on its mechanism of action BESPONSA may harm your unborn baby. You should not use BESPONSA during pregnancy, unless your doctor thinks that it is the best medicine for you.</p><p>&nbsp;</p><p>Contact your doctor immediately if you or your partner becomes pregnant during the period of treatment with this medicine.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Men and women should seek advice regarding fertility preservation before treatment.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>If you need treatment with BESPONSA, you must stop breast‑feeding during treatment and for at least 2&nbsp;months after treatment. Talk to your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>If you feel unusually tired (this is a very common side effect of BESPONSA), you should not drive or use machines.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor, pharmacist, or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>&nbsp;</p><p><strong>How BESPONSA is given</strong></p><p>&nbsp;</p><ul><li>Your doctor will decide on the correct dose.</li><li>A doctor or nurse will give you BESPONSA through a drip in your vein (intravenous infusion) which will run for 1&nbsp;hour.</li><li>Each dose is given weekly and each treatment cycle is 3&nbsp;doses.</li><li>If the medicine works well and you are going to receive a stem cell transplant (see section 2), you may receive 2 cycles or a maximum of 3&nbsp;cycles of treatment.</li><li>If the medicine works well, but you are not going to receive a stem cell transplant (see section 2), you may receive up to a maximum of 6&nbsp;cycles of treatment.</li><li>If you do not respond to the medicine within 3&nbsp;cycles, your treatment will be stopped.</li></ul><ul><li>Your doctor may change your dose, interrupt, or completely stop treatment with BESPONSA if you have certain side effects.</li><li>Your doctor may lower your dose based on your response to treatment.</li><li>Your doctor will do blood tests during the treatment to check for side effects and for response to treatment.</li></ul><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p><p><strong>&nbsp;</strong></p><p><strong>Medicines given before treatment with BESPONSA </strong></p><p>&nbsp;</p><p>Before your treatment with BESPONSA, you will be given other medicines (pre-medications) to help reduce infusion reactions and other possible side effects. These may include corticosteroids (e.g., dexamethasone), antipyretics (medicines to reduce fever), and antihistamines (medicines to reduce allergic reactions).</p><p>&nbsp;</p><p>Before your treatment with BESPONSA, you may be given medicines and be hydrated to prevent tumour lysis syndrome from occurring. Tumour lysis syndrome is associated with a variety of symptoms in the stomach and intestines (for example, nausea, vomiting, diarrhoea), heart (for example, changes in the rhythm), kidney (for example, decreased urine, blood in urine), and nerves and muscles (for example, muscular spasms, weakness, cramps).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these side effects may be serious.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately</strong> if you have signs and symptoms of any of the following serious side effects:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infusion related reaction (see section 2); signs and symptoms include fever and chills or breathing problems during or shortly after the BESPONSA infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; venoocclusive liver disease (see section 2); signs and symptoms include rapid weight gain, pain in the upper right side of your abdomen, increase in the size of the liver, accumulation of fluid causing abdominal swelling, and increases in bilirubin and/or liver enzymes (that may result in yellowing of the skin or eyes).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of blood cells known as neutrophils, (sometimes accompanied with fever), red blood cells, white blood cells, lymphocytes, or low number of blood components known as platelets (see section 2); signs and symptoms include developing an infection or fever or bruising easily or getting nose bleeds on a regular basis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tumour lysis syndrome (see section 2); this may be associated with a variety of symptoms in the stomach and intestines (for example, nausea, vomiting, diarrhoea), heart (for example, changes in the rhythm), kidney (for example, decreased urine, blood in urine), and nerves and muscles (for example, muscular spasms, weakness, cramps).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QT interval prolongation (see section 2); signs and symptoms include a change in electrical activity of the heart that can cause serious irregular heart rhythms. Tell your doctor if you have symptoms, such as dizziness, lightheadedness or fainting.</p><p>&nbsp;</p><p>Other side effects may include:</p><p>&nbsp;</p><p><strong>Very common</strong><em> </em>(may affect more than 1 in 10 people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced number of white blood cells which may result in general weakness and a tendency to develop infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced number of lymphocytes (a type of white blood cells) which may result in a tendency to develop infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced number of red blood cells which may result in fatigue and shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced number of platelets which may results in bleeding tendency</p><ul><li>Decreased appetite</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the abdomen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mouth inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised bilirubin level which may result in a yellowish colour in the skin, eyes, and other tissues</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High levels of liver enzymes (which can be indicators of liver injury) in the blood</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>&nbsp;</p><ul><li>Reduction in the number of various types of blood cells</li><li>Excess of uric acid in the blood</li><li>Excessive accumulation of fluid in the abdomen</li><li>Swelling of the abdomen</li><li>Changes in heart rhythm (may show on electrocardiogram)</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormally high levels of amylase (an enzyme needed for digestion and conversion of starch into sugars) in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormally high levels of lipase (an enzyme needed to process dietary fat) in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>To Report any Side effect(s):</strong></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center ( NPC )</strong></p><p>&middot;&nbsp;&nbsp; Fax: +966 11 205 7662</p><p>&middot;&nbsp;&nbsp; Call NPC at 00966 11 2038222, Exts: 2317-2356-2353-2354-2334-2340</p><p>&middot;&nbsp;&nbsp; Toll-Free phone: 8002490000</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP. The expiry date refers to the last day of that month.</p><p><u>&nbsp;</u></p><p><u>Unopened vial</u></p><p>&nbsp;</p><p>- &nbsp;&nbsp;&nbsp; Store in a refrigerator (2&nbsp;&deg;C‑8&nbsp;&deg;C).</p><p>- &nbsp;&nbsp;&nbsp; Store in the original carton in order to protect from light.</p><p>- &nbsp;&nbsp;&nbsp; Do not freeze.</p><p>&nbsp;</p><p><u>Reconstituted solution</u></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Use immediately or store in a refrigerator (2&nbsp;&deg;C‑8&nbsp;&deg;C) for up to 4 hours.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Protect from light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p><u>&nbsp;</u></p><p><u>Diluted solution </u></p><p><u>&nbsp;</u></p><p>- &nbsp;&nbsp;&nbsp; Use immediately or store at room temperature (20&nbsp;&deg;C‑25&nbsp;&deg;C) or in a refrigerator (2&nbsp;&deg;C‑8&nbsp;&deg;C). The maximum time from reconstitution through administration should be &le; 8 hours, with &le; 4 hours between reconstitution and dilution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Protect from light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p>&nbsp;</p><p>This medicine should be inspected visually for particulate matter and discolouration prior to administration. If particles or discolouration are observed, do not use.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your doctor how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is inotuzumab ozogamicin. Each vial contains 1&nbsp;mg inotuzumab ozogamicin. After reconstitution, 1&nbsp;mL of solution contains 0.25&nbsp;mg inotuzumab ozogamicin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sucrose, polysorbate&nbsp;80, sodium chloride, and tromethamine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                BESPONSA is a powder for concentrate for solution for infusion. 

Each pack of BESPONSA contains:

•	1 glass vial containing a white to off-white lyophilised cake or powder.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Inc., USA</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Wyeth Pharmaceutical Division of Wyeth Holdings LLC, a subsidiary of Pfizer Inc.<br /><br />401 North Middletown Road, Pearl River, NY 10965, USA</p><p><br />Packaging &amp; Released by<br /><br />Pharmacia and Upjohn Company<br /><br />7000 Portage Road, Kalamazoo, Michigan 49001, USA<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 August 2017 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المكون الفعال في بيسبونسا هو إينوتوزوماب أوزوجاميسين. ينتمي هذا الدواء إلى مجموعة من الأدوية تستهدف الخلايا السرطانية. تُسمى هذه الأدوية بالعوامل المضادة للأورام.</p><p>&nbsp;</p><p>يُستخدم بيسبونسا لعلاج البالغين المصابين بابيضاض الدم الأرومي الليمفاوي الحاد. ابيضاض الدم الأرومي الليمفاوي الحاد هو سرطان دم يكون فيه لديك عدد كبير للغاية من خلايا الدم البيضاء.</p><p>&nbsp;</p><p>&nbsp;</p><p>يعمل بيسبونسا من خلال الارتباط بالخلايا التي تحتوي على بروتين يسمى CD22. تحتوي الخلايا المصابة بابيضاض الدم الأرومي الليمفاوي على هذا البروتين. بمجرد الارتباط بالخلايا المصابة بابيضاض الدم الأرومي الليمفاوي، يقوم الدواء بتوصيل مادة داخل الخلايا تتداخل مع الحمض النووي (DNA) للخلايا وتقتلها في النهاية.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم بيسبونسا إذا:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالحساسية تجاه إينوتوزوماب أوزوجاميسين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد أصبت من قبل بحالة شديدة تم تأكيدها من مرض الانسداد الوريدي (حالة تتلف فيها الأوعية الدموية في الكبد وتتعرض للانسداد بواسطة الجلطات الدموية) أو إذا كنت مصابًا في الوقت الحالي بمرض الانسداد الوريدي.</p><ul><li>كنت مصابًا بمرض خطير مستمر في الكبد، مثل تشمّع الكبد (حالة لا يعمل فيها الكبد على النحو الصحيح بسبب وجود تلف طويل الأمد)، فرط التنسج العقيدي المتجدد (حالة مصحوبة بعلامات وأعراض ارتفاع ضغط الدم البابي يمكن أن تحدث بسبب الاستخدام المزمن للأدوية)، التهاب الكبد النشط (مرض يتسم بالتهاب الكبد).</li></ul><p><strong>&nbsp;</strong></p><p><strong>تحذيرات واحتياطات </strong></p><p>&nbsp;</p><p>تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام بيسبونسا إذا:</p><p>&nbsp;</p><ul><li>كان لديك تاريخ من الإصابة بمشكلات في الكبد أو أمراض في الكبد أو إذا ظهرت عليك علامات وأعراض الإصابة بحالة خطيرة تُسمى مرض الانسداد الوريدي الكبدي، وهي حالة تتلف فيها الأوعية الدموية في الكبد وتتعرض للانسداد بواسطة الجلطات الدموية. يمكن أن يكون مرض الانسداد الوريدي مميتًا وهو يرتبط بوجود زيادة سريعة في الوزن، وألم في الجانب العلوي الأيمن من بطنك، وزيادة في حجم الكبد، وتراكم للسوائل يسبب تورم البطن، وزيادة في نسبة البيليروبين و/أو إنزيمات الكبد تظهر من خلال فحوصات الدم (والتي يمكن أن تتسبب في اصفرار الجلد أو العينين). يمكن أن تحدث هذه الحالة أثناء العلاج باستخدام بيسبونسا أو بعد العلاج اللاحق بعملية زراعة الخلايا الجذعية. زراعة الخلايا الجذعية هي إجراء يتم لزراعة خلايا جذعية (وهي خلايا تتطور لتصبح خلايا دم جديدة) خاصة بشخص آخر في مجرى دمك. يمكن أن يتم هذا الإجراء إذا استجاب مرضك تمامًا للعلاج.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهرت عليك علامات أو أعراض انخفاض في عدد خلايا الدم المعروفة باسم العدلات (في بعض الأحيان يكون مصحوبًا بالحمى)، أو خلايا الدم الحمراء، أو خلايا الدم البيضاء، أو الليمفاويات، أو انخفاض في عدد مكونات الدم المعروفة باسم الصفيحات الدموية؛ تتضمن هذه العلامات والأعراض الإصابة بالعدوى أو الحمى أو التكدم بسهولة، أو الإصابة بنزيف في الأنف بشكل متكرر.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهرت عليك أعراض وعلامات حدوث تفاعل مرتبط بالتسريب، مثل الحمى والقشعريرة أو وجود مشكلات في التنفس أثناء إجراء تسريب بيسبونسا أو بعده بفترة قصيرة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهرت عليك أعراض وعلامات متلازمة تحلل الورم، التي قد تكون مصحوبة بأعراض في المعدة والأمعاء (مثل الغثيان، القيء، الإسهال)، والقلب (مثل التغيرات في نظم القلب)، والكلى (مثل انخفاض معدل التبول، ظهور دم في البول)، والأعصاب والعضلات (مثل التشنجات العضلية، ضعف العضلات، الشد العضلي)، أثناء إجراء تسريب بيسبونسا أو بعده بفترة قصيرة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك تاريخ من الإصابة، أو كانت لديك قابلية للإصابة، بإطالة فترة QT (وهو تغير في النشاط الكهربي للقلب يمكن أن يسبب حالة خطيرة من اضطراب نظم القلب)، و/أو كنت تتناول أدوية يُعرف بأنها تطيل فترة QT، و/أو كانت لديك مستويات غير طبيعية من الكهارل (مثل الكالسيوم، المغنيسيوم، البوتاسيوم).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك ارتفاع في مستويات إنزيم الأميلاز أو إنزيم الليباز الذي قد يكون علامة على وجود مشكلات لديك في البنكرياس أو الكبد والمرارة أو القنوات الصفراوية.</p><p><strong>&nbsp;</strong></p><p><strong>أخبري طبيبكِ أو الصيدلي أو الممرضة على الفور </strong>إذا أصبحتِ حاملًا أثناء فترة العلاج باستخدام بيسبونسا وبعد انتهاء فترة العلاج لمدة تصل إلى 8 أشهر.</p><p>&nbsp;</p><p>سيجري طبيبك فحوصات دم بشكل منتظم لمراقبة تعدادات دمك أثناء العلاج باستخدام بيسبونسا. انظر أيضًا القسم 4.</p><p>&nbsp;</p><p>أثناء العلاج، خاصة في الأيام القليلة الأولى بعد بدء العلاج، يمكن أن ينخفض تعداد خلايا دمك البيضاء بشدة (قلة العدلات)، وقد يصحب ذلك حمى (قلة العدلات الحموية).</p><p>&nbsp;</p><p>أثناء العلاج، وخاصة في الأيام القليلة الأولى بعد بدء العلاج، يمكن أن تتعرض لارتفاع في مستويات إنزيمات الكبد. سيجري طبيبك فحوصات دم بشكل منتظم لمراقبة إنزيمات كبدك أثناء العلاج باستخدام بيسبونسا.</p><p>&nbsp;</p><p>يمكن أن يتسبب العلاج باستخدام بيسبونسا في إطالة فترة QT (وهي تغير في النشاط الكهربي للقلب يمكن أن يسبب حالة خطيرة من اضطراب نظم القلب). سيجري طبيبك مخططًا كهربيًا للقلب (ECG) وفحوصات دم لقياس مستوى الكهارل (مثل الكالسيوم، المغنيسيوم، البوتاسيوم) قبل أول جرعة من بيسبونسا وسيكرر هذه الاختبارات أثناء العلاج. انظر أيضًا القسم 4.</p><p>&nbsp;</p><p>سيقوم طبيبك أيضًا بمراقبة حالتك لرصد علامات وأعراض متلازمة تحلل الورم بعد أن تتلقى بيسبونسا. انظر أيضًا القسم 4.</p><p><strong>&nbsp;</strong></p><p><strong>الأطفال والمراهقون</strong></p><p>&nbsp;</p><p>ينبغي عدم استخدام بيسبونسا مع الأطفال والمراهقين البالغين من العمر أقل من 18 عامًا لعدم توفر بيانات عن هذه الفئة.</p><p>&nbsp;</p><p><strong>الأدوية الأخرى وبيسبونسا</strong></p><p>&nbsp;</p><p>أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. يتضمن هذا الأدوية التي يتم الحصول عليها دون وصفة طبية والأدوية العشبية.</p><p><strong>&nbsp;</strong></p><p><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p><strong>&nbsp;</strong></p><p>إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الممرضة قبل استخدام هذا الدواء.</p><p><strong>&nbsp;</strong></p><p><u>منع الحمل </u></p><p>&nbsp;</p><p>يجب أن يتجنب الرجال إنجاب الأطفال، وأن تتجنب السيدات الحمل. يجب أن تستخدم السيدات وسيلة فعالة لمنع الحمل أثناء العلاج ولمدة 8 أشهر على الأقل بعد تلقّي آخر جرعة من العلاج. يجب أن يستخدم الرجال وسيلة فعالة لمنع الحمل أثناء العلاج ولمدة 5 أشهر على الأقل بعد تلقّي آخر جرعة من العلاج.</p><p><strong>&nbsp;</strong></p><p><u>الحمل</u></p><p>&nbsp;</p><p>آثار بيسبونسا على السيدات الحوامل غير معروفة، لكن بناءً على آلية عمله فقد يسبب بيسبونسا ضررًا لجنينكِ. ينبغي عليكِ عدم استخدام بيسبونسا أثناء الحمل، ما لم يعتقد طبيبكِ أنه أفضل دواء بالنسبة لكِ.</p><p>&nbsp;</p><p>تواصلي مع طبيبكِ على الفور إذا أصبحتِ حاملًا أو إذا أصبحت زوجتك حاملًا أثناء فترة العلاج بهذا الدواء.</p><p>&nbsp;</p><p><u>الخصوبة</u></p><p>&nbsp;</p><p>ينبغي أن يطلب الرجال والسيدات المشورة بشأن طرق حفظ الخصوبة قبل العلاج.</p><p>&nbsp;</p><p><u>الرضاعة الطبيعية</u></p><p>&nbsp;</p><p>إذا تطلبت حالتكِ العلاج باستخدام بيسبونسا، يجب عليكِ إيقاف الرضاعة الطبيعية أثناء العلاج ولمدة شهرين على الأقل بعد العلاج. تحدثي إلى طبيبكِ.</p><p><strong>&nbsp;</strong></p><p><strong>القيادة واستخدام الآلات</strong></p><p>&nbsp;</p><p>إذا شعرت بالتعب بشكل غير معتاد (هذا أحد الآثار الجانبية الشائعة جدًا لبيسبونسا)، فلا تقم بالقيادة أو استخدام الآلات.</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دائمًا على استخدام هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي أو الممرضة. راجع طبيبك أو الصيدلي أو الممرضة إذا كنت غير متأكد مما يجب عليك فعله.</p><p>&nbsp;</p><p><strong>كيف يتم إعطاء بيسبونسا</strong></p><p>&nbsp;</p><ul><li>سوف يقرر طبيبك الجرعة الصحيحة.</li><li>سيقوم طبيب أو ممرضة بإعطائك بيسبونسا من خلال التنقيط في وريدك (تسريب عن طريق الوريد)، والذي سيستمر بدوره لمدة ساعة واحدة.</li><li>ستُعطى كل جرعة أسبوعيًا وتتكون كل دورة علاج من 3&nbsp;جرعات.</li><li>إذا كان الدواء فعالًا وتقرر أنك ستخضع لعملية زراعة خلايا جذعية (انظر القسم 2)، فقد تتلقى دورتين أو 3 دورات بحد أقصى من العلاج.</li><li>إذا كان الدواء فعالًا، لكنك لن تخضع لعملية زراعة خلايا جذعية (انظر القسم 2)، فقد تتلقى ما يصل إلى 6 دورات من العلاج بحد أقصى.</li><li>إذا لم تستجب للدواء خلال 3 دورات، فسوف يتم إيقاف علاجك.</li></ul><ul><li>يمكن أن يغير طبيبك جرعتك أو يقطع العلاج باستخدام بيسبونسا أو يوقفه تمامًا إذا أصبت بآثار جانبية معينة.</li><li>يمكن أن يقوم طبيبك بتقليل جرعتك بناءً على استجابتك للعلاج.</li><li>سيجري طبيبك فحوصات دم أثناء العلاج لرصد ظهور الآثار الجانبية والتحقق من الاستجابة للعلاج.</li></ul><p>&nbsp;</p><p>إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>الأدوية التي يتم إعطاؤها قبل العلاج باستخدام بيسبونسا </strong></p><p>&nbsp;</p><p>قبل علاجك باستخدام بيسبونسا، سيتم إعطاؤك أدوية أخرى (أدوية تحضيرية) للمساعدة في تقليل التفاعلات الناتجة عن التسريب والآثار الجانبية المحتملة الأخرى. قد تتضمن هذه الأدوية الستيرويدات القشرية (مثل ديكساميثازون)، ومضادات الحمى (أدوية لخفض الحمى)، ومضادات الهيستامين (أدوية لتقليل تفاعلات الحساسية).</p><p>&nbsp;</p><p>قبل أن يتم علاجك باستخدام بيسبونسا، قد يتم إعطاؤك أدوية وتزويدك بالسوائل لمنع الإصابة بمتلازمة تحلل الورم. ترتبط متلازمة تحلل الورم بمجموعة مختلفة من الأعراض تصيب المعدة والأمعاء (مثل الغثيان، القيء، الإسهال) والقلب (مثل التغيرات في نظم القلب)، والكلى (مثل انخفاض معدل التبول، ظهور دم في البول)، والأعصاب والعضلات (مثل التشنجات العضلية، ضعف العضلات، الشد العضلي).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع. وقد يكون بعض هذه الآثار الجانبية خطيرًا.</p><p>&nbsp;</p><p><strong>أخبر طبيبك على الفور</strong> إذا ظهرت عليك العلامات والأعراض المرتبطة بأي مما يلي من الآثار الجانبية الخطيرة:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل مرتبط بالتسريب (انظر القسم 2)؛ تتضمن العلامات والأعراض الحمى والقشعريرة أو مشكلات في التنفس أثناء تسريب بيسبونسا أو بعده بفترة قصيرة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الانسداد الوريدي في الكبد (انظر القسم 2)؛ تتضمن العلامات والأعراض زيادة سريعة في الوزن، وألم في الجانب العلوي الأيمن من بطنك، وزيادة في حجم الكبد، وتراكم للسوائل يسبب تورم البطن، وزيادة في نسبة البيليروبين و/أو إنزيمات الكبد (والتي يمكن أن تتسبب في اصفرار الجلد أو العينين).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم المعروفة بالعدلات، (في بعض الأحيان يكون مصحوبًا بالحمى)، أو خلايا الدم الحمراء، أو خلايا الدم البيضاء، أو الليمفاويات، أو انخفاض في عدد مكونات الدم المعروفة باسم الصفيحات الدموية (انظر القسم 2)؛ تتضمن العلامات والأعراض الإصابة بالعدوى أو الحمى أو التكدم بسهولة أو الإصابة بنزيف في الأنف بشكل منتظم.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة تحلل الورم (انظر القسم 2)؛ قد تكون مرتبطة بمجموعة مختلفة من الأعراض تصيب المعدة والأمعاء (مثل الغثيان، القيء، الإسهال) والقلب (مثل التغيرات في نظم القلب)، والكلى (مثل انخفاض معدل التبول، ظهور دم في البول)، والأعصاب والعضلات (مثل التشنجات العضلية، ضعف العضلات، الشد العضلي).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إطالة فترة QT (انظر القسم 2)؛ تتضمن العلامات والأعراض تغيرًا في النشاط الكهربي للقلب يمكن أن يسبب حالة خطيرة من اضطراب نظم القلب. أخبر طبيبك إذا أصبت بأعراض، مثل الدوار، أو الدوخة، أو الإغماء.</p><p>&nbsp;</p><p>قد تتضمن الآثار الجانبية الأخرى:</p><p>&nbsp;</p><p><strong>شائعة جدًا</strong><em> </em>(قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء والذي قد ينتج عنه ضعف عام وقابلية للإصابة بالعدوى</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الليمفاويات (وهي نوع من أنواع خلايا الدم البيضاء) قد تنتج عنه قابلية للإصابة بالعدوى</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء والذي قد ينتج عنه الإرهاق وضيق التنفس</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية الذي قد يؤدي الي ميل للنزيف</p><ul><li>ضعف الشهية</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى البيليروبين والذي قد ينتج عنه اصفرار لون الجلد والعينين وأنسجة أخرى</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيمات الكبد (والذي قد يكون مؤشرًا على إصابة الكبد) في الدم</p><p>&nbsp;</p><p><strong>شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل 10 أشخاص):</p><p>&nbsp;</p><ul><li>انخفاض في عدد أنواع مختلفة من خلايا الدم</li><li>زيادة حمض اليوريك في الدم</li><li>تراكم مفرط للسوائل في البطن</li><li>تورم البطن</li><li>تغيرات في نظم القلب (قد تظهر في مخطط كهربية القلب)</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع غير طبيعي في مستويات الأميلاز (وهو إنزيم ضروري لهضم النشا وتحويلها إلى سكريات) في الدم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع غير طبيعي في مستويات الليباز (إنزيم ضروري لمعالجة الدهون الغذائية) في الدم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحساسية</p><p>&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>&nbsp;</p><p>إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي بشأنها. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>للإبلاغ عن أي أثر جانبي (آثار جانبية):</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>المركز الوطني للتيقظ والسلامة الدوائية (</strong><strong>NPC</strong><strong>)</strong></p><p><strong><em>&middot;&nbsp;&nbsp; </em></strong>فاكس: +966 11 205 7662</p><p><strong><em>&middot;&nbsp;&nbsp; </em></strong>اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على الرقم 00966 11 2038222، تحويلة: 2317-2356-2353-2354-2334-2340</p><p><strong><em>&middot;&nbsp;&nbsp; </em></strong>الهاتف المجاني: 8002490000</p><p><strong><em>&middot;&nbsp;&nbsp; </em></strong>البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق القارورة والعبوة الكرتونية بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p><u>&nbsp;</u></p><p><u>القوارير غير المفتوحة</u></p><p>&nbsp;</p><p>- &nbsp;&nbsp;&nbsp; خزنها في الثلاجة (من درجتين مئويتين إلى 8 درجات مئوية).</p><p>- &nbsp;&nbsp;&nbsp; خزنها في عبوتها الكرتونية الأصلية لحمايتها من الضوء.</p><p>- &nbsp;&nbsp;&nbsp; لا تقم بتجميدها.</p><p>&nbsp;</p><p><u>المحلول المحضَّر</u></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; استخدمه على الفور أو قم بتخزينه في الثلاجة (من درجتين مئويتين إلى 8 درجات مئوية) لمدة تصل إلى 4 ساعات.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; احفظه بعيدًا عن الضوء.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بتجميده.</p><p><u>&nbsp;</u></p><p><u>المحلول المخفَّف </u></p><p><u>&nbsp;</u></p><p>- &nbsp;&nbsp;&nbsp; استخدمه على الفور أو قم بتخزينه في درجة حرارة الغرفة (من 20 درجة مئوية إلى 25 درجة مئوية) أو في الثلاجة (من درجتين مئويتين إلى 8 درجات مئوية). ينبغي أن يكون الحد الأقصى للفترة بين التحضير والاستعمال أقل من أو تساوي 8 ساعات، مع فترة أقل من أو تساوي 4 ساعات بين التحضير والتخفيف.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; احفظه بعيدًا عن الضوء.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بتجميده.</p><p>&nbsp;</p><p>ينبغي فحص هذا الدواء بالنظر للتأكد من عدم وجود جسيمات وعدم تغير اللون قبل الاستعمال. إذا تمت ملاحظة جسيمات أو تغير اللون، فلا تستخدمه.</p><p>&nbsp;</p><p>لا تتخلص من أي دواء عبر مياه الصرف أو مع المخلفات المنزلية. اسأل طبيبك عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>محتويات بيسبونسا </strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إينوتوزوماب أوزوجاميسين. تحتوي كل قارورة على 1 ملجم من إينوتوزوماب أوزوجاميسين. بعد التحضير، سيحتوي 1 مل من المحلول على 0.25 ملجم من إينوتوزوماب أوزوجاميسين.</p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المكونات الأخرى هي سكروز، وبوليسوربات 80، وكلوريد الصوديوم، وتروميثامين.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            بيسبونسا هو مسحوق يستخدم لتحضير ركازة لإعداد محلول مخصص للتسريب. 

تحتوي كل عبوة من بيسبونسا على:

•	قارورة زجاجية واحدة تحتوي على كتلة أو مسحوق مجفف بالتجميد لونه بين الأبيض إلى الأبيض المائل للصفرة.


        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك تصريح التسويق</strong></p><p>&nbsp;</p><p><strong>. USA</strong><strong>Pfizer Inc</strong></p><p>&nbsp;</p><p><strong>الجهة المصنعة</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Wyeth Pharmaceutical Division of Wyeth Holdings LLC, a subsidiary of Pfizer Inc</strong>.</p><p><strong>401 North Middletown Road, Pearl River, NY 10965, USA</strong></p><p>&nbsp;</p><p><strong>الجهة المغلفة والفسح النهائي</strong></p><p>&nbsp;</p><p><strong>Pharmacia and Upjohn Company</strong></p><p>&nbsp;</p><p><strong>7000 Portage Road, Kalamazoo, Michigan 49001, USA</strong></p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BESPONSA 0.9MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inotuzumab ozogamicin is a CD22-directed antibody-drug conjugate (ADC) consisting of 3 components: 1) the recombinant humanized immunoglobulin class G subtype 4 (IgG4) kappa antibody inotuzumab, specific for human CD22, 2) N-acetyl gamma calicheamicin that causes double-stranded DNA breaks, and 3) an acid cleavable linker composed of the condensation product of 4-(4’-acetylphenoxy)-butanoic acid (AcBut) and 3-methyl-3-mercaptobutane hydrazide (known as dimethylhydrazide) that covalently attaches N-acetyl gamma calicheamicin to inotuzumab. 
 

Inotuzumab ozogamicin has an approximate molecular weight of 160 kDa. The average number of calicheamicin derivative molecules conjugated to each inotuzumab molecule is approximately 6 with a distribution from 2-8. Inotuzumab ozogamicin is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the semisynthetic calicheamicin derivative is produced by microbial fermentation followed by synthetic modification. 

BESPONSA (inotuzumab ozogamicin) for Injection is supplied as a sterile, white to off white, preservative free, lyophilized powder for intravenous administration. Each single-dose vial delivers 0.9 mg inotuzumab ozogamicin. Inactive ingredients are polysorbate 80 (0.36 mg), sodium chloride (2.16 mg), sucrose (180 mg), and tromethamine (8.64 mg). After reconstitution with 4 mL of Sterile Water for Injection, USP, the final concentration is 0.25 mg/mL of inotuzumab ozogamicin with a deliverable volume of 3.6 mL (0.9 mg) and a pH of approximately 8.0. 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                For Injection: 0.9 mg as a white to off-white lyophilized powder in a single dose vial for reconstitution and further dilution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.2.1&nbsp; </strong><strong>Recommended Dosage</strong></p><p><strong>&nbsp;</strong></p><p><strong>Pre-medicate before each dose<em> </em></strong><em>[see 4.2 Posology and method of administration</em><em>]. </em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the first cycle, the recommended total dose of BESPONSA for all patients is 1.8&nbsp;mg/m<sup>2</sup> per cycle, administered as 3 divided doses on Day 1 (0.8&nbsp;mg/m<sup>2</sup>), Day 8 (0.5&nbsp;mg/m<sup>2</sup>), and Day 15 (0.5&nbsp;mg/m<sup>2</sup>). Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), and/or to allow recovery from toxicity.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For subsequent cycles:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients who achieve a CR or CRi, the recommended total dose of BESPONSA is 1.5&nbsp;mg/m<sup>2</sup> per cycle, administered as 3 divided doses on Day 1 (0.5&nbsp;mg/m<sup>2</sup>), Day 8 (0.5&nbsp;mg/m<sup>2</sup>), and Day&nbsp;15 (0.5&nbsp;mg/m<sup>2</sup>). Subsequent cycles are 4 weeks in duration.</p><p>&nbsp;</p><p>OR</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients who do not achieve a CR or CRi, the recommended total dose of BESPONSA is 1.8&nbsp;mg/m<sup>2</sup> per cycle given as 3 divided doses on Day 1 (0.8&nbsp;mg/m<sup>2</sup>), Day 8 (0.5&nbsp;mg/m<sup>2</sup>), and Day 15&nbsp;(0.5&nbsp;mg/m<sup>2</sup>). Subsequent cycles are 4 weeks in duration. Patients who do not achieve a CR or CRi within 3 cycles should discontinue treatment.</p><p>&nbsp;</p><p>For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with BESPONSA is 2 cycles. A third cycle may be considered for those patients who do not achieve CR or CRi and minimal residual disease (MRD) negativity after 2 cycles <em>[see 4.4&nbsp;&nbsp; Special warnings and precautions for use</em><em>].</em><em> </em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients not proceeding to HSCT, additional cycles of treatment, up to a maximum of 6 cycles, may be administered.</p><p>&nbsp;</p><p>Table 1 shows the recommended dosing regimens.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><thead><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 1. &nbsp;&nbsp;&nbsp; Dosing Regimen for Cycle 1 and Subsequent Cycles Depending on Response to Treatment </strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Day 1</strong></p></td><td style="vertical-align:top"><p><strong>Day 8<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Day 15<sup>a</sup></strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Dosing regimen for Cycle 1</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All patients:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dose<sup>b</sup></p></td><td style="vertical-align:top"><p>0.8 mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>0.5 mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>0.5 mg/m<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Cycle length</p></td><td colspan="3" style="vertical-align:top"><p>21 days<sup>c</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Dosing regimen for subsequent cycles depending on response to treatment</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Patients who have achieved a CR<sup>d</sup> or CRi<sup>e</sup>:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dose<sup>b</sup></p></td><td style="vertical-align:top"><p>0.5 mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>0.5 mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>0.5 mg/m<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Cycle length</p></td><td colspan="3" style="vertical-align:top"><p>28 days<sup>f</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Patients who have not achieved a CR<sup>d</sup> or CRi<sup>e</sup>:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dose<sup>b</sup></p></td><td style="vertical-align:top"><p>0.8 mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>0.5 mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>0.5 mg/m<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Cycle length</p></td><td colspan="3" style="vertical-align:top"><p>28 days<sup>f</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Abbreviations: CR=complete remission; CRi=complete remission with incomplete hematologic recovery.</p><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp; </sup>+/- 2 days (maintain minimum of 6 days between doses).</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp; </sup>Dose is based on the patient&rsquo;s body surface area (m<sup>2</sup>).</p><p><sup>c&nbsp;&nbsp;&nbsp;&nbsp; </sup>For patients who achieve a CR or a CRi, and/or to allow for recovery from toxicity, the cycle length may be extended up to 28 days (i.e., 7-day treatment-free interval starting on Day 21).</p><p><sup>d&nbsp;&nbsp;&nbsp;&nbsp; </sup>CR is defined as &lt; 5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, full recovery of peripheral blood counts (platelets &ge; 100&nbsp;&times;&nbsp;10<sup>9</sup>/L and absolute neutrophil counts [ANC] &ge; 1&nbsp;&times;&nbsp;10<sup>9</sup>/L) and resolution of any extramedullary disease.</p><p><sup>e&nbsp;&nbsp;&nbsp;&nbsp; </sup>CRi is defined as &lt; 5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, incomplete recovery of peripheral blood counts (platelets &lt; 100&nbsp;&times;&nbsp;10<sup>9</sup>/L and/or ANC &lt; 1&nbsp;&times;&nbsp;10<sup>9</sup>/L) and resolution of any extramedullary disease.</p><p><sup>f&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>7-day treatment-free interval starting on Day 21.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>4.2.2&nbsp;&nbsp; Recommended Pre-medications and Cytoreduction</p><p>&nbsp;</p><p>Premedication with a corticosteroid, antipyretic, and antihistamine is recommended prior to dosing. Patients should be observed during and for at least 1 hour after the end of infusion for symptoms of infusion related reactions <em>[see </em><em>4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</em><em>].</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients with circulating lymphoblasts, cytoreduction with a combination of hydroxyurea, steroids, and/or vincristine to a peripheral blast count of less than or equal to 10,000/mm<sup>3</sup> is recommended prior to the first dose.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>4.2.3 Dose Modification</p><p>&nbsp;</p><p>Modify the dose of BESPONSA for toxicities (see Tables 2-4). BESPONSA doses within a treatment cycle (i.e., Days 8 and/or 15) do not need to be interrupted due to neutropenia or thrombocytopenia, but dosing interruptions within a cycle are recommended for non-hematologic toxicities. If the dose is reduced due to BESPONSA-related toxicity, the dose must not be re-escalated.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 2. &nbsp;&nbsp;&nbsp; BESPONSA&nbsp; Dose Modifications for Hematologic Toxicities</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Criteria</strong></p></td><td style="vertical-align:top"><p><strong>BESPONSA Dose Modification(s)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>If prior to BESPONSA treatment ANC was greater than or equal to 1&nbsp;&times;&nbsp;10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>If ANC decreases, then interrupt the next cycle of treatment until recovery of ANC to greater than or equal to 1&nbsp;&times;&nbsp;10<sup>9</sup>/L. Discontinue BESPONSA if low ANC persists for greater than 28&nbsp;days and is suspected to be related to BESPONSA.</p></td></tr><tr><td style="vertical-align:top"><p>If prior to BESPONSA treatment platelet count was greater than or equal to 50&nbsp;&times;&nbsp;10<sup>9</sup>/L<sup>a </sup></p></td><td style="vertical-align:top"><p>If platelet count decreases, then interrupt the next cycle of treatment until platelet count recovers to greater than or equal to 50&nbsp;&times;&nbsp;10<sup>9</sup>/L<sup>a</sup>. Discontinue BESPONSA if low platelet count persists for greater than 28 days and is suspected to be related to BESPONSA.</p></td></tr><tr><td style="vertical-align:top"><p>If prior to BESPONSA treatment ANC was less than 1&nbsp;&times;&nbsp;10<sup>9</sup>/L and/or platelet count was less than 50&nbsp;&times;&nbsp;10<sup>9</sup>/L<sup>a</sup></p></td><td style="vertical-align:top"><p>If ANC or platelet count decreases, then interrupt the next cycle of treatment until at least one of the following occurs:</p><p>- ANC and platelet counts recover to at least baseline levels for the prior cycle, or</p><p>- ANC recovers to greater than or equal to 1&nbsp;&times;&nbsp;10<sup>9</sup>/L and platelet count recovers to greater than or equal to 50&nbsp;&times;&nbsp;10<sup>9</sup>/L<sup>a</sup>, or</p><p>- Stable or improved disease (based on most recent bone marrow assessment) and the ANC and platelet count decrease is considered to be due to the underlying disease (not considered to be BESPONSA-related toxicity).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Abbreviation: ANC=absolute neutrophil count.</em></p><p><em><sup>a&nbsp;&nbsp;&nbsp;&nbsp; </sup></em>Platelet count used for dosing should be independent of blood transfusion.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 3. &nbsp;&nbsp;&nbsp; &nbsp;BESPONSA Dose Modifications for Non-hematologic Toxicities </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Non-hematologic Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Dose Modification(s)</strong></p></td></tr><tr><td style="vertical-align:top"><p>VOD or other severe liver toxicity</p></td><td style="vertical-align:top"><p>Permanently discontinue treatment <em>[see </em><em>4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</em><em>].</em></p></td></tr><tr><td style="vertical-align:top"><p>Total bilirubin greater than 1.5&nbsp;&times;&nbsp;ULN and AST<strong>/</strong>ALT greater than 2.5&nbsp;&times;&nbsp;ULN</p></td><td style="vertical-align:top"><p>Interrupt dosing until recovery of total bilirubin to less than or equal to 1.5&nbsp;&times;&nbsp;ULN<em> </em>and AST/ALT to less than or equal to 2.5&nbsp;&times;&nbsp;ULN prior to each dose unless due to Gilbert&rsquo;s syndrome or hemolysis. Permanently discontinue treatment if total bilirubin does not recover to less than or equal to 1.5&nbsp;&times;&nbsp;ULN or AST/ALT does not recover to less than or equal to 2.5&nbsp;&times;&nbsp;ULN <em>[see 4.4Special warnings and precautions for use</em><em>].</em></p></td></tr><tr><td style="vertical-align:top"><p>Infusion related reaction</p></td><td style="vertical-align:top"><p>Interrupt the infusion and institute appropriate medical management. Depending on the severity of the infusion related reaction, consider discontinuation of the infusion or administration of steroids and antihistamines. For severe or life-threatening infusion reactions, permanently discontinue treatment <em>[see 4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</em><em>].</em></p></td></tr><tr><td style="vertical-align:top"><p>Non-hematologic toxicity greater than or equal to Grade 2<sup>a</sup></p></td><td style="vertical-align:top"><p>Interrupt treatment until recovery to Grade 1 or pre-treatment grade levels prior to each dose.</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Abbreviations: ALT=alanine aminotransferase; </em>AST=<em>aspartate aminotransferase; ULN=upper limit of normal; VOD=venoocclusive disease.</em></p><p><sup>a &nbsp;&nbsp;&nbsp; </sup>Severity grade according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="2" style="vertical-align:bottom"><p><strong>Table 4.&nbsp;&nbsp;&nbsp;&nbsp; BESPONSA Dose Modifications Depending on Duration of Dosing Interruption Due to Non-Hematologic Toxicity Toxicities </strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Duration of Dose Interruption Due to Toxicity</strong></p></td><td style="vertical-align:bottom"><p><strong>Dose Modification(s)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Less than 7 days (within a cycle)</p></td><td style="vertical-align:top"><p>Interrupt the next dose (maintain a minimum of 6 days between doses).</p></td></tr><tr><td style="vertical-align:top"><p>Greater than or equal to 7 days</p></td><td style="vertical-align:top"><p>Omit the next dose within the cycle.</p></td></tr><tr><td style="vertical-align:top"><p>Greater than or equal to 14 days</p></td><td style="vertical-align:top"><p>Once adequate recovery is achieved, decrease the total dose by 25% for the subsequent cycle. If further dose modification is required, then reduce the number of doses to 2 per cycle for subsequent cycles. If a 25% decrease in the total dose followed by a decrease to 2 doses per cycle is not tolerated, then permanently discontinue treatment.</p></td></tr><tr><td style="vertical-align:top"><p>Greater than 28 days</p></td><td style="vertical-align:top"><p>Consider permanent discontinuation of treatment.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.4.1&nbsp;&nbsp;&nbsp; Hepatotoxicity, Including Hepatic Veno-occlusive Disease (VOD) (also known as Sinusoidal Obstruction Syndrome)</p><p>&nbsp;</p><p>In the INO‑VATE ALL trial, hepatotoxicity, including severe, life‑threatening, and sometimes fatal hepatic VOD was observed in 23/164 patients (14%) in the BESPONSA arm during or following treatment or following a HSCT after completion of treatment. VOD was reported up to 56&nbsp;days after the last dose during treatment or during follow‑up without an intervening HSCT. The median time from subsequent HSCT to onset of VOD was 15&nbsp;days (range: 3‑57 days). In the BESPONSA arm, among the 79 patients who proceeded to a subsequent HSCT, VOD was reported in 18/79 patients (23%), and among all 164 patients treated, VOD was reported in 5/164 patients (3%) during study therapy or in follow-up without an intervening HSCT.</p><p>&nbsp;</p><p>The risk of VOD was greater in patients who underwent HSCT after BESPONSA treatment; use of HSCT conditioning regimens containing 2 alkylating agents (e.g., busulfan in combination with other alkylating agents) and last total bilirubin level greater than or equal to the ULN before HSCT are significantly associated with an increased risk of VOD. Other risk factors for VOD in patients treated with BESPONSA included ongoing or prior liver disease, prior HSCT, increased age, later salvage lines, and a greater number of BESPONSA treatment cycles. Patients who have experienced prior VOD or have serious ongoing hepatic liver disease (e.g., cirrhosis, nodular regenerative hyperplasia, active hepatitis) are at an increased risk for worsening of liver disease, including developing VOD, following treatment with BESPONSA.</p><p>&nbsp;</p><p>Monitor closely for signs and symptoms of VOD; these may include elevations in total bilirubin, hepatomegaly (which may be painful), rapid weight gain, and ascites. Due to the risk of VOD, for patients proceeding to HSCT, the recommended duration of treatment with BESPONSA is 2 cycles; a third cycle may be considered for those patients who do not achieve a CR or CRi and MRD negativity after 2 cycles <em>[see 4.2 Posology and method of administration</em><em>]. </em>For patients who proceed to HSCT, monitor liver tests closely during the first month post‑HSCT, then less frequently thereafter, according to standard medical practice.</p><p>&nbsp;</p><p>In the INO‑VATE ALL trial, increases in liver tests were reported. Grade 3/4 AST, ALT, and total bilirubin abnormal liver tests occurred in 7/160 (4%), 7/161 (4%), and 8/161 patients (5%), respectively.&nbsp;</p><p>&nbsp;</p><p>In all patients, monitor liver tests, including ALT, AST, total bilirubin, and alkaline phosphatase, prior to and following each dose of BESPONSA. Elevations of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA &nbsp;<em>[see</em><em> 4.2 Posology and method of administration</em><em>].</em></p><p>&nbsp;</p><p><strong>4.4.2&nbsp;&nbsp;&nbsp; Increased Risk of Post-Transplant Non-Relapse Mortality</strong></p><p>&nbsp;</p><p>In the INO‑VATE ALL trial, a higher post-HSCT non-relapse mortality rate was observed in patients receiving BESPONSA compared to the Investigator&rsquo;s choice of chemotherapy arm, resulting in a higher Day 100 post-HSCT mortality rate.</p><p>&nbsp;</p><p>Overall, 79/164 patients (48%) in the BESPONSA arm and 35/162 patients (22%) in the Investigator&rsquo;s choice of chemotherapy arm had a follow-up HSCT. The post-HSCT non-relapse mortality rate was 31/79 (39%) and 8/35 (23%) in the BESPONSA arm compared to the Investigator&rsquo;s choice of chemotherapy arm, respectively.</p><p>&nbsp;</p><p>In the BESPONSA arm, the most common causes of post-HSCT non-relapse mortality included VOD and infections. Five of the 18 VOD events that occurred post-HSCT were fatal. In the BESPONSA arm, among patients with ongoing VOD at time of death, 6 patients died due to multiorgan failure (MOF) or infection (3 patients died due to MOF, 2 patients died due to infection, and 1 patient died due to MOF and infection).</p><p>&nbsp;</p><p>Monitor closely for toxicities post-HSCT, including signs and symptoms of infection and VOD <em>[see </em><em>4.4 Special warnings and precautions for use</em><em>]. </em></p><p>&nbsp;</p><p>4.4.3&nbsp;&nbsp;&nbsp; Myelosuppression</p><p>&nbsp;</p><p>In the INO‑VATE ALL trial, myelosuppression was observed in patients receiving BESPONSA <em>[see Adverse Reactions (6.1)]</em>.</p><p>&nbsp;</p><p>Thrombocytopenia and neutropenia were reported in 83/164 patients (51%) and 81/164 patients (49%), respectively. Grade 3 thrombocytopenia and neutropenia were reported in 23/164 patients (14%) and 33/164 patients (20%), respectively. Grade 4 thrombocytopenia and neutropenia were reported in 46/164&nbsp;patients (28%) and 45/164 patients (27%), respectively. Febrile neutropenia, which may be life‑threatening, was reported in 43/164 patients (26%). For patients who were in CR or CRi at the end of treatment, the recovery of platelet counts to &gt;&nbsp;50,000/mm<sup>3</sup> was later than 45 days after the last dose in 15/164 patients (9%) who received BESPONSA and 3/162 patients (2%) who received Investigator&rsquo;s choice of chemotherapy.</p><p>&nbsp;</p><p><strong>4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Complications associated with myelosuppression (including infections and bleeding/hemorrhagic events) were observed in patients receiving BESPONSA <em>[see</em><em> 4.8 Undesirable effects</em><em>].</em><em> </em>Infections, including serious infections, some of which were life-threatening or fatal, were reported in 79/164 patients (48%). Fatal infections, including pneumonia, neutropenic sepsis, sepsis, septic shock, and pseudomonal sepsis, were reported in 8/164 patients (5%). Bacterial, viral, and fungal infections were reported.</p><p>&nbsp;</p><p>Hemorrhagic events were reported in 54/164 patients (33%). Grade 3 or 4 hemorrhagic events were reported in 8/164&nbsp;patients (5%). One Grade 5 (fatal) hemorrhagic event (intra-abdominal hemorrhage) was reported in 1/164 patients (1%). The most common hemorrhagic event was epistaxis which was reported in 24/164 patients (15%).</p><p>&nbsp;</p><p>Monitor complete blood counts prior to each dose of BESPONSA and monitor for signs and symptoms of infection, bleeding/hemorrhage, or other effects of myelosuppression during treatment with BESPONSA. As appropriate, administer prophylactic anti‑infectives and employ surveillance testing during and after treatment with BESPONSA. Management of severe infection, bleeding/hemorrhage, or other effects of myelosuppression, including severe neutropenia or thrombocytopenia, may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA <em>[see Dosage and Administration (2.</em><em>3</em><em>)</em><em>].</em></p><p>&nbsp;</p><p>4.4.4&nbsp;&nbsp;&nbsp; Infusion Related Reactions</p><p>&nbsp;</p><p>In the INO‑VATE ALL trial, infusion related reactions were observed in patients who received BESPONSA. Infusion related reactions (all Grade 2) were reported in 4/164 patients (2%). Infusion related reactions generally occurred in Cycle 1 shortly after the end of the BESPONSA infusion and resolved spontaneously or with medical management.</p><p>&nbsp;</p><p>Premedicate with a corticosteroid, antipyretic, and antihistamine prior to dosing<em> [see </em><em>4.2&nbsp;&nbsp; Posology and method of administration</em><em>]. </em></p><p>&nbsp;</p><p>Monitor patients closely during and for at least 1&nbsp;hour after the end of infusion for the potential onset of infusion related reactions, including symptoms such as fever, chills, rash, or breathing problems. Interrupt infusion and institute appropriate medical management if an infusion related reaction occurs. Depending on the severity of the infusion related reaction, consider discontinuation of the infusion or administration of steroids and antihistamines. For severe or life‑threatening infusion reactions, permanently discontinue BESPONSA <em>[see </em><em>4.2 Posology and method of administration</em><em>].</em></p><p>&nbsp;</p><p>4.4.5&nbsp;&nbsp;&nbsp; QT Interval Prolongation</p><p>&nbsp;</p><p>In the INO‑VATE ALL trial, increases in QT interval corrected for heart rate using Fridericia&rsquo;s formula (QTcF) of &ge; to 60&nbsp;msec from baseline were measured in 4/162 patients (3%). No patients had QTcF values greater than 500&nbsp;msec <em>[see </em><em>&nbsp;5.&nbsp;&nbsp; PHARMACOLOGICAL PROPERTIES</em><em>].</em> Grade 2 QT prolongation was reported in 2/164 patients (1%). No &ge; Grade 3 QT prolongation or events of Torsade de Pointes were reported <em>[see 4.8 Undesirable effects]</em>.</p><p>&nbsp;</p><p>Administer BESPONSA with caution in patients who have a history of or predisposition for QTc prolongation, who are taking medicinal products that are known to prolong QT interval <em>[see Drug Interactions (7)]</em>, and in patients with electrolyte disturbances <em>[see Drug Interactions (7)].</em> Obtain electrocardiograms (ECGs) and electrolytes prior to the start of treatment, after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment <em>[see</em> <em>4.5 Interaction with other medicinal products and other forms of interaction ,</em> <em>5.1 Pharmacodynamics properties ]</em>.</p><p>&nbsp;</p><p>4.4.6&nbsp;&nbsp;&nbsp; Embryo‑Fetal Toxicity</p><p>&nbsp;</p><p>Based on its mechanism of action and findings from animal studies, BESPONSA can cause embryo‑fetal harm when administered to a pregnant woman. In animal studies, inotuzumab ozogamicin caused embryo‑fetal toxicities, starting at a dose that was approximately 0.4 times the exposure in patients at the maximum recommended dose, based on the area under the concentration‑time curve (AUC). Advise females of reproductive potential to use effective contraception during treatment with BESPONSA and for at least 8 months after the final dose of BESPONSA. Advise males with female partners of reproductive potential to use effective contraception during treatment with BESPONSA and for at least 5&nbsp;months after the last dose of BESPONSA. Apprise pregnant women of the potential risk to the fetus. Advise women to contact their healthcare provider if they become pregnant or if pregnancy is suspected during treatment with BESPONSA<em> </em><em>[see</em> <em>4.6 Fertility, Pregnancy and Lactation </em>,<em> 5. Pharmacological Properties , 5.3 Preclinical safety data&nbsp; ].</em></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Drugs That Prolong the QT Interval</u></p><p><u>&nbsp;</u></p><p>Concomitant use of BESPONSA with drugs known to prolong the QT interval or induce Torsades de Pointes may increase the risk of a clinically significant QTc interval prolongation <em>[see 5.1 Pharmacodynamics properties]</em>. Discontinue or use alternative concomitant drugs that do not prolong QT/QTc interval while the patient is using BESPONSA. When it is not feasible to avoid concomitant use of drugs known to prolong QT/QTc, obtain ECGs and electrolytes prior to the start of treatment, after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment <em>[see </em><em>4.4 Special warnings and precautions for use </em><em>]</em>.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.6.1&nbsp;&nbsp;&nbsp; Pregnancy</p><p>&nbsp;</p><p><u>Risk Summary </u></p><p><u>&nbsp;</u></p><p>Based on its mechanism of action and findings from animal studies <em>[see </em><em>5. Pharmacological properties], </em><em>Nonclinical Toxicology</em><em> (13.1)</em><em>]</em>, BESPONSA can cause embryo‑fetal harm when administered to a pregnant woman<em>.</em> There are no available data on BESPONSA use in pregnant women to inform a drug‑associated risk of major birth defects and miscarriage. In rat embryo‑fetal development studies, inotuzumab ozogamicin caused embryo‑fetal toxicity at maternal systemic exposures that were &ge;&nbsp;0.4&nbsp;times the exposure in patients at the maximum recommended dose, based on AUC <em>[see Data]</em>. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, advise the patient of the potential risk to a fetus.</p><p>&nbsp;</p><p>Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.</p><p><u>&nbsp;</u></p><p><u>Data</u></p><p><u>&nbsp;</u></p><p><em>Animal Data </em></p><p><em>&nbsp;</em></p><p>In embryo‑fetal development studies in rats, pregnant animals received daily intravenous doses of inotuzumab ozogamicin up to 0.36&nbsp;mg/m<sup>2</sup> during the period of organogenesis. Embryo-fetal toxicities including increased resorptions and fetal growth retardation as evidenced by decreased live fetal weights and delayed skeletal ossification were observed at &ge;&nbsp;0.11 mg/m<sup>2</sup> (approximately 2&nbsp;times the exposure in patients at the maximum recommended dose, based on AUC). Fetal growth retardation also occurred at 0.04&nbsp;mg/m<sup>2 </sup>(approximately 0.4 times the exposure in patients at the maximum recommended dose, based on AUC).</p><p>&nbsp;</p><p>In an embryo-fetal development study in rabbits, pregnant animals received daily intravenous doses up to 0.15 mg/m<sup>2</sup> (approximately 3 times the exposure in patients at the maximum recommended dose, based on AUC) during the period of organogenesis. At a dose of 0.15&nbsp;mg/m<sup>2</sup>, slight maternal toxicity was observed in the absence of any effects on embryo‑fetal development.</p><p>&nbsp;</p><p>4.6.2&nbsp;&nbsp;&nbsp; Lactation</p><p>&nbsp;</p><p><u>Risk Summary </u></p><p><u>&nbsp;</u></p><p>There are no data on the presence of inotuzumab ozogamicin or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.&nbsp; Because of the potential for adverse reactions in breastfed infants, advise women not to breastfeed during treatment with BESPONSA and for at least 2&nbsp;months after the last dose.</p><p><u>&nbsp;</u></p><p>4.6.3&nbsp;&nbsp;&nbsp; Females and Males of Reproductive Potential</p><p>&nbsp;</p><p><u>Pregnancy Testing</u></p><p><u>&nbsp;</u></p><p>Based on its mechanism of action and findings from animal studies, BESPONSA can cause embryo‑fetal harm when administered to a pregnant woman<em> [see </em><em>4.6 Fertility, Pregnancy and Lactation </em><em>,</em><em> 5.3 Preclinical safety data ] </em>Verify the pregnancy status of females of reproductive potential prior to initiating BESPONSA.</p><p><u>&nbsp;</u></p><p><u>Contraception</u></p><p><u>&nbsp;</u></p><p><em>Females</em></p><p><em>&nbsp;</em></p><p>Advise females of reproductive potential to avoid becoming pregnant while receiving BESPONSA. Advise females of reproductive potential to use effective contraception during treatment with BESPONSA and for at least 8&nbsp;months after the last dose <em>[see </em><em>5.3 Preclinical safety data </em><em>]</em>.</p><p>&nbsp;</p><p><em>Males</em></p><p><em>&nbsp;</em></p><p>Advise males with female partners of reproductive potential to use effective contraception during treatment with BESPONSA and for at least 5&nbsp;months after the last dose <em>[see </em><em>5.3 Preclinical safety data]</em>.</p><p><em>&nbsp;</em></p><p><u>Infertility</u></p><p><u>&nbsp;</u></p><p><em>Females</em></p><p>&nbsp;</p><p>Based on findings in animals, BESPONSA may impair fertility in females of reproductive potential <em>[see</em><em> 5.3 Preclinical safety data </em><em>]</em>.</p><p>&nbsp;</p><p><em>Males</em></p><p>&nbsp;</p><p>Based on findings in animals, BESPONSA may impair fertility in males of reproductive potential <em>[see</em><em> 5.3 Preclinical safety data </em><em>]</em>.</p><p>&nbsp;</p><p>4.6.4&nbsp;&nbsp;&nbsp; Pediatric Use</p><p>&nbsp;</p><p>Safety and effectiveness have not been established in pediatric patients.</p><p>&nbsp;</p><p>4.6.5&nbsp;&nbsp;&nbsp; Geriatric Use</p><p>&nbsp;</p><p>In the INO-VATE ALL trial, 30/164&nbsp;patients (18%) treated with BESPONSA were &ge;&nbsp;65&nbsp;years of age. No differences in responses were identified between older and younger patients.</p><p>&nbsp;</p><p>Based on a population pharmacokinetic analysis in 765&nbsp;patients, no adjustment to the starting dose is required based on age <em>[see </em><em>&nbsp;5.3 Preclinical safety data </em><em>]</em>.</p><p>&nbsp;</p><p>4.6.6&nbsp;&nbsp;&nbsp; Hepatic Impairment</p><p>&nbsp;</p><p>Based on a population pharmacokinetic analysis, the clearance of inotuzumab ozogamicin in patients with mild hepatic impairment (total bilirubin less than or equal to&nbsp;ULN and AST&nbsp;greater than&nbsp;ULN, or total bilirubin&nbsp;greater than 1.0‑1.5&nbsp;&times; ULN and AST any level; n=150) was similar to patients with normal hepatic function (total bilirubin/AST less than or equal to&nbsp;ULN; n=611). In patients with moderate (total bilirubin greater than 1.5‑3&nbsp;&times;&nbsp;ULN and AST any level; n=3) and severe hepatic impairment (total bilirubin greater than 3&nbsp;&times;&nbsp;ULN<em> </em>and AST any level; n=1), inotuzumab ozogamicin clearance did not appear to be reduced <em>[s</em><em>ee 5.3 Preclinical safety data </em><em>]</em><em>. </em></p><p>&nbsp;</p><p>No adjustment to the starting dose is required when administering BESPONSA to patients with total bilirubin less than or equal to 1.5&nbsp;&times;&nbsp;ULN and AST/ALT less than or equal to 2.5&nbsp;&times;&nbsp;ULN <em>[see </em><em>4.2 Posology and method of adminstration]. </em>There is limited safety information available in patients with total bilirubin greater than 1.5 &times;&nbsp;ULN and/or AST/ALT greater than 2.5&nbsp;&times;&nbsp;ULN prior to dosing. Interrupt dosing until recovery of total bilirubin to less than or equal to 1.5&nbsp;&times;&nbsp;ULN<em> </em>and AST/ALT to less than or equal to 2.5&nbsp;&times;&nbsp;ULN prior to each dose unless due to Gilbert&rsquo;s syndrome or hemolysis. Permanently discontinue treatment if total bilirubin does not recover to less than or equal to 1.5&nbsp;&times;&nbsp;ULN or AST/ALT does not recover to less than or equal to 2.5&nbsp;&times;&nbsp;ULN <em>[see </em><em>4.2 Posology and method of administration </em><em>, </em><em>4.4 Special warnings and precautions for use </em><em>]</em>.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ADVERSE REACTIONS</p><p>&nbsp;</p><p>The following adverse reactions are discussed in greater detail in other sections of the label:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatotoxicity, including hepatic VOD (also known as SOS) <em>[see </em><em>4.4 Special warnings and precautions for use </em><em>]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased risk of post-transplant non-relapse mortality<strong> </strong><em>[see </em><em>4.4 Special warnings and precautions for use </em><em>]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myelosuppression <em>[see </em><em>4.4 Special warnings and precautions for use </em><em>]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion related reactions <em>[see </em><em>4.4 Special warnings and precautions for use </em><em>]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QT interval prolongation <em>[see </em><em>4.4 Special warnings and precautions for use </em><em>]</em></p><p>&nbsp;</p><p>4.8.1&nbsp;&nbsp;&nbsp; Clinical Trials Experience</p><p>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p>The adverse reactions described in this section reflect exposure to BESPONSA in 164 patients with relapsed or refractory ALL who participated in a randomized clinical study of BESPONSA versus Investigator&rsquo;s choice of chemotherapy (fludarabine + cytarabine + granulocyte colony-stimulating factor [FLAG], mitoxantrone + cytarabine [MXN/Ara-C], or high dose cytarabine [HIDAC]) (INO‑VATE ALL Trial [NCT01564784]) <em>[see </em><em>5.4 Clinical studies </em><em>]</em>.</p><p>&nbsp;</p><p>Of the 164 patients who received BESPONSA, the median age was 47&nbsp;years (range: 18‑78 years), 56% were male, 68% had received 1 prior treatment regimen for ALL, 31% had received 2 prior treatment regimens for ALL, 68% were White, 19% were Asian, and 2% were Black.</p><p>&nbsp;</p><p>In patients who received BESPONSA, the median duration of treatment was 8.9 weeks (range:&nbsp;0.1‑26.4&nbsp;weeks), with a median of 3 treatment cycles started in each patient. In patients who received Investigator&rsquo;s choice of chemotherapy, the median duration of treatment was 0.9 weeks (range:&nbsp;0.1‑15.6&nbsp;weeks), with a median of 1 treatment cycle started in each patient.</p><p>In patients who received BESPONSA, the most common (&ge; 20%) adverse reactions were thrombocytopenia, neutropenia, infection, anemia, leukopenia, fatigue, hemorrhage, pyrexia, nausea, headache, febrile neutropenia, transaminases increased, abdominal pain, gamma-glutamyltransferase increased, and hyperbilirubinemia.</p><p>&nbsp;</p><p>In patients who received BESPONSA, the most common (&ge; 2%) serious adverse reactions were infection, febrile neutropenia, hemorrhage, abdominal pain, pyrexia, VOD, and fatigue.</p><p>&nbsp;</p><p>In patients who received BESPONSA, the most common (&ge; 2%) adverse reactions reported as the reason for permanent discontinuation were infection (6%), thrombocytopenia (2%), hyperbilirubinemia (2%), transaminases increased (2%), and hemorrhage (2%); the most common (&ge; 5%) adverse reactions reported as the reason for dosing interruption were neutropenia (17%), infection (10%), thrombocytopenia (10%), transaminases increased (6%), and febrile neutropenia (5%); and the most common (&ge; 1%) adverse reactions reported as the reason for dose reduction were neutropenia (1%), thrombocytopenia (1%), and transaminases increased (1%).</p><p>&nbsp;</p><p>VOD was reported in 23/164 patients (14%) who received BESPONSA during or following treatment or following a HSCT after completion of treatment <em>[</em><em>see 4.4 Special warnings and Precautions for use ]. </em></p><p>&nbsp;</p><p>Table 6 shows the adverse reactions with &ge; 10% incidence reported in patients with relapsed or refractory ALL who received BESPONSA or Investigator&rsquo;s choice of chemotherapy.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:678px"><thead><tr><td colspan="5" style="vertical-align:bottom"><p><strong>Table 6. &nbsp;&nbsp;&nbsp; Adverse Reactions With &ge; 10% Incidence<sup>a</sup> in Patients With Relapsed or Refractory B‑Cell Precursor ALL Who Received BESPONSA or Investigator&rsquo;s Choice of Chemotherapy (FLAG, MXN/Ara-C, or HIDAC) </strong></p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>Body System</strong></p><p><strong>Adverse Reaction</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>BESPONSA</strong></p><p><strong>(N=164)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>FLAG, MXN/Ara-C, or HIDAC </strong></p><p><strong>(N=143<sup>b</sup>)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Grades</strong></p></td><td style="vertical-align:top"><p><strong>&ge; Grade 3 </strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p></td><td style="vertical-align:top"><p><strong>&ge; Grade 3 </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Infections </strong></p></td></tr><tr><td style="vertical-align:top"><p>Infection<sup>c</sup></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>76</p></td><td style="vertical-align:top"><p>54</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>d</sup></p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>59</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>e</sup></p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>43</p></td></tr><tr><td style="vertical-align:top"><p>Anemia<sup>f</sup></p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>59</p></td><td style="vertical-align:top"><p>47</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia<sup>g</sup></p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>42</p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>53</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia<sup>h</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>26</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache<sup>i</sup></p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage<sup>j</sup></p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>k</sup></p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis<sup>l</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hyperbilirubinemia</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>m</sup></p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Transaminases increased<sup>n</sup></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Gamma-glutamyltransferase increased</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Adverse reactions included treatment-emergent all-causality events that commenced on or after Cycle 1 Day 1 within 42&nbsp;days after the last dose of BESPONSA, but prior to the start of a new anticancer treatment (including HSCT).</p><p>Preferred terms were retrieved by applying the Medical Dictionary for Regulatory Activities (MedDRA) version 18.1.</p><p>Severity grade of adverse reactions were according to NCI CTCAE version 3.0.</p><p>Abbreviations: ALL=acute lymphoblastic leukemia; FLAG=fludarabine + cytarabine + granulocyte colony-stimulating factor; HIDAC=high dose cytarabine; HSCT=hematopoietic stem cell transplant; MXN/Ara-C=mitoxantrone + cytarabine; N=number of patients; NCI CTCAE=National Cancer Institute Common Toxicity Criteria for Adverse Events.</p><p><sup>a&nbsp;&nbsp; </sup>Only adverse reactions with &ge; 10% incidence in the BESPONSA arm are included.</p><p><sup>b&nbsp;&nbsp; </sup>19 patients randomized to FLAG, MXN/Ara-C, or HIDAC did not receive treatment.</p><p><sup>c&nbsp;&nbsp; </sup>Infection includes any reported preferred terms for BESPONSA retrieved in the System Organ Class Infections and infestations.</p><p><sup>d&nbsp;&nbsp; </sup>Thrombocytopenia includes the following reported preferred terms: Platelet count decreased and Thrombocytopenia.</p><p><sup>e&nbsp;&nbsp; </sup>Neutropenia includes the following reported preferred terms: Neutropenia and Neutrophil count decreased.</p><p><sup>f&nbsp;&nbsp;&nbsp; </sup>Anemia includes the following reported preferred terms: Anemia and Hemoglobin decreased.</p><p><sup>g&nbsp;&nbsp; </sup>Leukopenia includes the following reported preferred terms: Leukopenia, Monocytopenia, and White blood cell count decreased.<sup> </sup></p><p><sup>h&nbsp;&nbsp; </sup>Lymphopenia includes the following reported preferred terms: B-lymphocyte count decreased, Lymphocyte count decreased, and Lymphopenia.</p><p><sup>i&nbsp;&nbsp;&nbsp; </sup>Headache includes the following reported preferred terms: Headache, Migraine, and Sinus headache.</p><p><sup>j&nbsp;&nbsp;&nbsp; </sup>Hemorrhage includes reported preferred terms for BESPONSA retrieved in the Standard MedDRA Query (narrow) for Hemorrhage terms (excluding laboratory terms), resulting in the following preferred terms: Conjunctival hemorrhage, Contusion, Ecchymosis, Epistaxis, Eyelid bleeding, Gastrointestinal hemorrhage, Gastritis hemorrhagic, Gingival bleeding, Hematemesis, Hematochezia, Hematotympanum, Hematuria, Hemorrhage intracranial, Hemorrhage subcutaneous, Hemorrhoidal hemorrhage, Intra-abdominal hemorrhage, Lip hemorrhage, Lower gastrointestinal hemorrhage, Mesenteric hemorrhage, Metrorrhagia, Mouth hemorrhage, Muscle hemorrhage, Oral mucosa hematoma, Petechiae, Post‑procedural hematoma, Rectal hemorrhage, Shock hemorrhagic, Subcutaneous hematoma, Subdural hematoma, Upper gastrointestinal hemorrhage, and Vaginal hemorrhage.</p><p><sup>k&nbsp;&nbsp; </sup>Abdominal pain includes the following reported preferred terms: Abdominal pain, Abdominal pain lower, Abdominal pain upper, Abdominal tenderness, Esophageal pain, and Hepatic pain.</p><p><sup>l&nbsp;&nbsp;&nbsp; </sup>Stomatitis includes the following reported preferred terms: Aphthous ulcer, Mucosal inflammation, Mouth ulceration, Oral pain, Oropharyngeal pain, and Stomatitis.</p><p><sup>m&nbsp; </sup>Fatigue includes the following reported preferred terms: Asthenia and Fatigue.</p><p><sup>n&nbsp;&nbsp; </sup>Transaminases increased includes the following reported preferred terms: Aspartate aminotransferase increased, Alanine aminotransferase increased, Hepatocellular injury, and Hypertransaminasemia.</p></td></tr></tbody></table><p>&nbsp;</p><p>Additional adverse reactions (all grades) that were reported in less than 10% of patients treated with BESPONSA included: lipase increased (9%), abdominal distension (6%), amylase increased (5%), hyperuricemia (4%), ascites (4%), infusion related reaction (2%; includes the following: hypersensitivity and infusion related reaction), pancytopenia (2%; includes the following: bone marrow failure, febrile bone marrow aplasia, and pancytopenia), tumor lysis syndrome (2%), and electrocardiogram QT prolonged (1%).</p><p>&nbsp;</p><p>Table 7 shows the clinically important laboratory abnormalities reported in patients with relapsed or refractory ALL who received BESPONSA or Investigator&rsquo;s choice of chemotherapy.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 7. &nbsp;&nbsp;&nbsp; Laboratory Abnormalities in Patients With Relapsed or Refractory B-Cell Precursor ALL Who Received </strong><strong>BESPONSA</strong><strong> or Investigator&rsquo;s Choice of Chemotherapy (FLAG, MXN/Ara-C, or HIDAC) </strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Laboratory Abnormality<sup>a</sup></strong></p></td><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>BESPONSA</strong></p></td><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>FLAG, MXN/Ara-C, or HIDAC </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3/4</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3/4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td></tr></thead><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Hematology </strong></p></td></tr><tr><td style="vertical-align:top"><p>Platelet count decreased</p></td><td style="vertical-align:top"><p>161</p></td><td style="vertical-align:top"><p>98</p></td><td style="vertical-align:top"><p>76</p></td><td style="vertical-align:top"><p>142</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>99</p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin decreased</p></td><td style="vertical-align:top"><p>161</p></td><td style="vertical-align:top"><p>94</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>142</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>70</p></td></tr><tr><td style="vertical-align:top"><p>Leukocytes decreased</p></td><td style="vertical-align:top"><p>161</p></td><td style="vertical-align:top"><p>95</p></td><td style="vertical-align:top"><p>82</p></td><td style="vertical-align:top"><p>142</p></td><td style="vertical-align:top"><p>99</p></td><td style="vertical-align:top"><p>98</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophil count decreased</p></td><td style="vertical-align:top"><p>160</p></td><td style="vertical-align:top"><p>94</p></td><td style="vertical-align:top"><p>86</p></td><td style="vertical-align:top"><p>130</p></td><td style="vertical-align:top"><p>93</p></td><td style="vertical-align:top"><p>88</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocytes (absolute) decreased</p></td><td style="vertical-align:top"><p>160</p></td><td style="vertical-align:top"><p>93</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>127</p></td><td style="vertical-align:top"><p>97</p></td><td style="vertical-align:top"><p>91</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Chemistry </strong></p></td></tr><tr><td style="vertical-align:top"><p>GGT increased</p></td><td style="vertical-align:top"><p>148</p></td><td style="vertical-align:top"><p>67</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>111</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>17</p></td></tr><tr><td style="vertical-align:top"><p>AST increased</p></td><td style="vertical-align:top"><p>160</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>134</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>ALP increased</p></td><td style="vertical-align:top"><p>158</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>133</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>ALT increased</p></td><td style="vertical-align:top"><p>161</p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>137</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Blood bilirubin increased</p></td><td style="vertical-align:top"><p>161</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>138</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Lipase increased</p></td><td style="vertical-align:top"><p>139</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>90</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricemia</p></td><td style="vertical-align:top"><p>158</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>122</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Amylase increased</p></td><td style="vertical-align:top"><p>143</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>102</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Severity grade of laboratory abnormalities according to NCI CTCAE version 3.0.</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Abbreviations: ALL=acute lymphoblastic leukemia; ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; FLAG=fludarabine + cytarabine + granulocyte colony-stimulating factor; GGT=gamma-glutamyltransferase; HIDAC=high dose cytarabine; MXN/Ara-C=mitoxantrone + cytarabine; N=number of patients; NCI CTCAE=National Cancer Institute Common Toxicity Criteria for Adverse Events.</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a</sup> Laboratory abnormalities were summarized up to the end of treatment + 42 days but prior to the start of a new anti-cancer therapy.</p></td></tr></tbody></table><p>&nbsp;</p><p>4.8.2&nbsp;&nbsp;&nbsp; Immunogenicity</p><p>&nbsp;</p><p>As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to inotuzumab ozogamicin in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.</p><p>&nbsp;</p><p>In clinical studies of BESPONSA in patients with relapsed or refractory ALL, the immunogenicity of BESPONSA was evaluated using an electrochemiluminescence (ECL)‑based immunoassay to test for anti-inotuzumab ozogamicin antibodies. For patients whose sera tested positive for anti‑inotuzumab ozogamicin antibodies, a cell‑based luminescence assay was performed to detect neutralizing antibodies.</p><p>&nbsp;</p><p>In clinical studies of BESPONSA in patients with relapsed or refractory ALL, 7/236 patients (3%) tested positive for anti‑inotuzumab ozogamicin antibodies. No patients tested positive for neutralizing anti‑inotuzumab ozogamicin antibodies. In patients who tested positive for anti‑inotuzumab ozogamicin antibodies, the presence of anti‑inotuzumab ozogamicin antibodies did not affect clearance following BESPONSA treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Reporting of adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local requirements. </u></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance and Drug Safety Centre ( NPC )</p><ul><li>Fax: +966 11 205 7662</li><li>Call NPC at 00966 11 2038222, Exts: 2317-2356-2353-2354-2334-2340</li><li>Toll-Free phone: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamics</p><p>&nbsp;</p><p>During the treatment period, the pharmacodynamic response to BESPONSA was characterized by the depletion of CD22-positive leukemic blasts.</p><p><u>&nbsp;</u></p><p><u>Cardiac Electrophysiology</u></p><p><u>&nbsp;</u></p><p>In a randomized clinical study in patients with relapsed or refractory ALL, increases in QTcF of &ge;&nbsp;60&nbsp;msec from baseline were measured in 4/162 patients (3%) in the BESPONSA arm and 3/124&nbsp;patients (2%)&nbsp; in the Investigator&rsquo;s choice of chemotherapy arm. Increases in QTcF of &gt;&nbsp;500&nbsp;msec were observed in none of the patients in the BESPONSA arm and 1/124 patients (1%) in the Investigator&rsquo;s choice of chemotherapy arm. Central tendency analysis of the QTcF interval changes from baseline showed that the highest mean (upper bound of the 2‑sided 90%&nbsp;CI) for QTcF was 15.3 (21.1)&nbsp;msec, which was observed at Cycle&nbsp;4/Day&nbsp;1/1&nbsp;hour in the BESPONSA arm <em>[see </em><em>4.4 Special warnings and precautions for use </em><em>]</em><em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The mean C<sub>max</sub> of inotuzumab ozogamicin was 308&nbsp;ng/mL. The mean simulated total AUC per cycle was 100,000&nbsp;ng&Yuml;h/mL. In patients with relapsed or refractory ALL, steady-state drug concentration was achieved by Cycle&nbsp;4. Following administration of multiple doses, a 5.3&nbsp;times accumulation of inotuzumab ozogamicin was predicted by Cycle&nbsp;4.</p><p>&nbsp;</p><p><u>Distribution </u></p><p><em>&nbsp;</em></p><p>N-acetyl-gamma-calicheamicin dimethylhydrazide is approximately 97% bound to human plasma proteins in vitro. In humans, the total volume of distribution of inotuzumab ozogamicin was approximately 12&nbsp;L.</p><p>&nbsp;</p><p><u>Elimination </u></p><p><em>&nbsp;</em></p><p>The pharmacokinetics of inotuzumab ozogamicin was well characterized by a 2‑compartment model with linear and time-dependent clearance components. In 234&nbsp;patients with relapsed or refractory ALL, the clearance of inotuzumab ozogamicin at steady state was 0.0333&nbsp;L/h and the terminal half‑life (t<sub>&frac12;</sub>) was 12.3&nbsp;days. Following administration of multiple doses, a 5.3&nbsp;times accumulation of inotuzumab ozogamicin was predicted by Cycle&nbsp;4.</p><p><u>&nbsp;</u></p><p><u>Metabolism </u></p><p><em>&nbsp;</em></p><p>In vitro, N-acetyl-gamma-calicheamicin dimethylhydrazide was primarily metabolized via nonenzymatic reduction. In humans, N-acetyl-gamma-calicheamicin dimethylhydrazide serum levels were typically below the limit of quantitation.</p><p>&nbsp;</p><p><u>Specific Populations</u><br />&nbsp;</p><p>The effect of intrinsic factors on inotuzumab ozogamicin pharmacokinetics was assessed using a population pharmacokinetic analysis unless otherwise specified. Age (18 to 92 years of age), sex, and race (Asian versus non-Asian [Caucasian, Black, and Unspecified]) had no clinically significant effect on the pharmacokinetics of inotuzumab ozogamicin. Body surface area was found to significantly affect inotuzumab ozogamicin disposition. BESPONSA is dosed based on body surface area <em>[see 4.2 Posology and method of administration]. </em></p><p>&nbsp;</p><p><u>Patients with Renal Impairment</u></p><p><u>&nbsp;</u></p><p>The clearance of inotuzumab ozogamicin in patients with mild renal impairment (creatinine clearance [CL<sub>cr; </sub>based on the Cockcroft-Gault formula] 60‑89 mL/min; n=237), moderate renal impairment (CL<sub>cr</sub>&nbsp;30‑59&nbsp;mL/min; n=122), or severe renal impairment (CL<sub>cr</sub> 15‑29 mL/min; n=4) was similar to patients with normal renal function (CL<sub>cr</sub> &ge;90&nbsp;mL/min; n=402). The safety and efficacy of inotuzumab ozogamicin in patients with end stage renal disease with or without hemodialysis is unknown.</p><p><u>&nbsp;</u></p><p><u>Patients with Hepatic Impairment</u></p><p><u>&nbsp;</u></p><p>The clearance of inotuzumab ozogamicin in patients with mild hepatic impairment (total bilirubin &le;ULN and AST&nbsp;&gt;&nbsp;ULN, or total bilirubin&nbsp;&gt;1.0‑1.5&nbsp;&times;&nbsp;ULN and AST any level; n=150) was similar to patients with normal hepatic function (total bilirubin/AST &le;ULN; n=611). There is insufficient data in patients with moderate and severe hepatic impairment (total bilirubin &gt;1.5 ULN).</p><p><u>&nbsp;</u></p><p><u>Drug Interactions</u></p><p><em>&nbsp;</em></p><p><em>In vitro</em></p><p><em>&nbsp;</em></p><p><em>Effect of </em><em>Metabolic Pathways and Transporter Systems</em><em> on </em><em>BESPONSA</em><em> </em></p><p><u>&nbsp;</u></p><p>N-acetyl-gamma-calicheamicin dimethylhydrazide is a substrate of P‑glycoprotein (P-gp).</p><p>&nbsp;</p><p><em>Effect of BESPONSA on </em><em>Metabolic Pathways and Transporter Systems</em></p><p><u>&nbsp;</u></p><p>At clinically relevant concentrations, N-acetyl-gamma-calicheamicin dimethylhydrazide had a low potential to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Inhibit cytochrome P450 (</em><em>CYP </em><em>450) Enzymes</em>: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Induce CYP450 Enzymes</em>: CYP1A2, CYP2B6, and CYP3A4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Inhibit </em><em>UGT</em><em> Enzymes</em>: UGT1A1, UGT1A4, UGT1A6, UGT1A9, and UGT2B7.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Inhibit </em><em>Drug Transporter</em><em>s</em>: P‑gp, breast cancer resistance protein (BCRP), organic anion transporter (OAT)1 and OAT3, organic cation transporter (OCT)2, and organic anion transporting polypeptide (OATP)1B1 and OATP1B3.</p><p>&nbsp;</p><p>At clinically relevant concentrations, inotuzumab ozogamicin had a low potential to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Inhibit CYP450 Enzymes</em>: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Induce</em><em> </em><em>CYP450 Enzymes</em>: CYP1A2, CYP2B6, and CYP3A4.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NONCLINICAL TOXICOLOGY</p><p>&nbsp;</p><p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p><p>&nbsp;</p><p>Formal carcinogenicity studies have not been conducted with inotuzumab ozogamicin. In toxicity studies, rats were dosed weekly for 4 or 26&nbsp;weeks with inotuzumab ozogamicin at doses up to 4.1&nbsp;mg/m<sup>2</sup> and 0.73&nbsp;mg/m<sup>2</sup>, respectively. After 26&nbsp;weeks of dosing, rats developed hepatocellular adenomas in the liver at 0.73&nbsp;mg/m<sup>2</sup> (approximately 2&nbsp;times the exposure in patients at the maximum recommended dose, based on AUC).</p><p>&nbsp;</p><p>Inotuzumab ozogamicin was clastogenic in vivo in the bone marrow of male mice that received single doses &ge;1.1&nbsp;mg/m<sup>2</sup>. This is consistent with the known induction of DNA breaks by calicheamicin. N‑acetyl-gamma-calicheamicin dimethylhydrazide (the cytotoxic agent released from inotuzumab ozogamicin) was mutagenic in an in vitro bacterial reverse mutation (Ames) assay.</p><p>&nbsp;</p><p>In a female fertility and early embryonic development study, female rats were administered daily intravenous doses of inotuzumab ozogamicin up to 0.11 mg/m<sup>2</sup> for 2 weeks before mating through Day 7 of pregnancy. An increase in the proportion of resorptions and decrease in the number of viable embryos and gravid uterine weights were observed at the 0.11 mg/m<sup>2</sup> dose level (approximately 2 times the exposure in patients at the maximum recommended dose, based on AUC). Additional findings in female reproductive organs occurred in repeat-dose toxicology studies and included decreased ovarian and uterine weights, and ovarian and uterine atrophy. Findings in male reproductive organs occurred in repeat-dose toxicology studies and included decreased testicular weights, testicular degeneration, hypospermia, and prostatic and seminal vesicle atrophy. Testicular degeneration and hypospermia were nonreversible following a 4‑week nondosing period. In the chronic studies of 26-weeks duration, adverse effects on reproductive organs occurred at &ge;0.07 mg/m<sup>2</sup> in male rats and at 0.73 mg/m<sup>2</sup> in female monkeys <em>[see 4.6 Fertility, Pregnancy and lactation ]</em>.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>5.4 Clinical studies </strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Patients With Relapsed or Refractory ALL &ndash; </strong><strong>INO-VATE ALL</strong></p><p><strong>&nbsp;</strong></p><p>The safety and efficacy of BESPONSA were evaluated in INO-VATE ALL (NCT01564784) a randomized (1:1), open‑label, international, multicenter study in patients with relapsed or refractory ALL. Patients were stratified at randomization based on duration of first remission (&lt;&nbsp;12 months or &ge;&nbsp;12&nbsp;months, salvage treatment (Salvage 1 or 2) and patient age at randomization (&lt;&nbsp;55 or &ge;&nbsp;55 years). Eligible patients were &ge;&nbsp;18&nbsp;years of age with Philadelphia chromosome-negative or Philadelphia chromosome-positive relapsed or refractory B‑cell precursor ALL. All patients were required to have &ge;&nbsp;5% bone marrow blasts and to have received 1 or 2 previous induction chemotherapy regimens for ALL. Patients with Philadelphia chromosome‑positive B‑cell precursor ALL were required to have disease that failed treatment with at least 1&nbsp;tyrosine kinase inhibitor and standard chemotherapy. Table&nbsp;1 shows the dosing regimen used to treat patients.</p><p>&nbsp;</p><p>Among all 326&nbsp;patients who were randomized to receive BESPONSA (N=164) or Investigator&rsquo;s choice of chemotherapy (N=162), 215&nbsp;patients (66%) had received 1&nbsp;prior treatment regimen for ALL and 108&nbsp;patients (33%) had received 2&nbsp;prior treatment regimens for ALL. The median age was 47&nbsp;years (range:&nbsp;18‑79 years), 276&nbsp;patients (85%) had Philadelphia chromosome‑negative ALL, 206&nbsp;patients (63%) had a duration of first remission &lt;&nbsp;12 months, and 55&nbsp;patients (17%) had undergone a HSCT prior to receiving BESPONSA or Investigator&rsquo;s choice of chemotherapy. The two treatment groups were generally balanced with respect to the baseline demographics and disease characteristics.</p><p>&nbsp;</p><p>All evaluable patients had B‑cell precursor ALL that expressed CD22, with &ge;&nbsp;90% of evaluable patients exhibiting &ge;&nbsp;70% leukemic blast CD22 positivity prior to treatment, as assessed by flow cytometry performed at a central laboratory.</p><p>&nbsp;</p><p>The efficacy of BESPONSA was established on the basis of CR, the duration of CR, and proportion of MRD-negative CR (&lt;&nbsp;1 x 10<sup>-4</sup> of bone marrow nucleated cells by flow cytometry) in the first 218 patients randomized. CR, duration of remission (DoR), and MRD results in the initial 218&nbsp;randomized patients were consistent with those seen in all 326&nbsp;randomized patients.</p><p>&nbsp;</p><p>Among the initial 218&nbsp;randomized patients, 64/88&nbsp;(73%) and 21/88&nbsp;(24%) of responding patients per EAC achieved CR/CRi in Cycles 1 and 2, respectively, in the BESPONSA arm, and 29/32&nbsp;(91%) and 1/32&nbsp;(3%) of responding patients per EAC achieved a CR/CRi in Cycles 1 and 2, respectively, in the Investigator&rsquo;s choice of chemotherapy arm.</p><p>&nbsp;</p><p>Table 8 shows the efficacy results from this study.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><thead><tr><td colspan="10" style="vertical-align:top"><p><strong>Table 8. &nbsp;&nbsp;&nbsp; Efficacy Results in Patients With Relapsed or Refractory B‑Cell Precursor ALL Who Received BESPONSA or Investigator&rsquo;s Choice of Chemotherapy (FLAG, MXN/Ara‑C, or HIDAC)</strong></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>CR<sup>a</sup></strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>CRi<sup>b</sup></strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>CR/CRi<sup>a,b</sup></strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>BESPONSA</strong></p><p><strong>(N=109)</strong></p></td><td style="vertical-align:top"><p><strong>HIDAC, </strong></p><p><strong>FLAG, or MXN/Ara-C</strong></p><p><strong>(N=109)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>BESPONSA</strong></p><p><strong>(N=109)</strong></p></td><td style="vertical-align:top"><p><strong>HIDAC, </strong></p><p><strong>FLAG or MXN/Ara-C</strong></p><p><strong>(N=109)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>BESPONSA</strong></p><p><strong>(N=109)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HIDAC, </strong></p><p><strong>FLAG, or MXN/Ara-C</strong></p><p><strong>(N=109)</strong></p></td></tr><tr><td colspan="10" style="vertical-align:top"><p><strong>Responding (CR/CRi) patients</strong></p></td></tr><tr><td style="vertical-align:top"><p>n (%)</p><p>[95% CI]</p></td><td colspan="2"><p>39 (35.8)</p><p>[26.8-45.5]</p></td><td><p>19 (17.4)</p><p>[10.8-25.9]</p></td><td colspan="2"><p>49 (45.0)</p><p>[35.4-54.8]</p></td><td><p>13 (11.9)</p><p>[6.5-19.5]</p></td><td><p>88 (80.7)</p><p>[72.1-87.7]</p></td><td colspan="2"><p>32 (29.4)</p><p>[21.0-38.8]</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>c</sup></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>&lt;0.0001</strong></p></td></tr><tr><td colspan="10" style="vertical-align:top"><p>DoR<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>39</p></td><td colspan="2" style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>45</p></td><td colspan="2" style="vertical-align:top"><p>14</p></td><td colspan="2" style="vertical-align:top"><p>84</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p>Median, months</p><p>[95% CI]</p></td><td style="vertical-align:top"><p>8.0<br />[4.9-10.4]</p></td><td colspan="2" style="vertical-align:top"><p>4.9<br />[2.9-7.2]</p></td><td style="vertical-align:top"><p>4.6<br />[3.7-5.7]</p></td><td colspan="2" style="vertical-align:top"><p>2.9<br />[0.6-5.7]</p></td><td colspan="2" style="vertical-align:top"><p>5.4</p><p>[4.2-8.0]</p></td><td style="vertical-align:top"><p>3.5<br />[2.9-6.6]</p></td></tr><tr><td colspan="10" style="vertical-align:top"><p><strong>MRD-negativity<sup>e</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>35</p></td><td colspan="2" style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>34</p></td><td colspan="2" style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>69</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Rate<sup>f</sup> (%)</p><p>[95% CI]</p></td><td style="vertical-align:top"><p><strong>35/39 (89.7)</strong></p><p>[75.8-97.1]</p></td><td colspan="2" style="vertical-align:top"><p>6/19 (31.6) [12.6-56.6]</p></td><td style="vertical-align:top"><p>34/49 (69.4)</p><p>[54.6-81.7]</p></td><td colspan="2" style="vertical-align:top"><p>3/13 (23.1)</p><p>[5.0-53.8]</p></td><td colspan="2" style="vertical-align:top"><p><strong>69/88 (78.4)</strong></p><p>[68.4-86.5]</p></td><td style="vertical-align:top"><p><strong>9/32 (28.1)</strong></p><p>[13.7-46.7]</p></td></tr><tr><td colspan="10" style="vertical-align:top"><p>Abbreviations: CI=confidence interval; CR=complete remission; CRi=complete remission with incomplete hematologic recovery; DoR=duration of remission; EAC=Endpoint Adjudication Committee; FLAG=fludarabine + cytarabine + granulocyte colony-stimulating factor; HIDAC=high-dose cytarabine; HR=hazard ratio; MRD=minimal residual disease; MXN/AraC=mitoxantrone&nbsp;+&nbsp;cytarabine; N/n=number of patients; OS=overall survival; PFS=progression-free survival.</p></td></tr><tr><td colspan="10" style="vertical-align:top"><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp; </sup>CR, per EAC, was defined as &lt;&nbsp;5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, full recovery of peripheral blood counts (platelets &ge;&nbsp;100&nbsp;&times;&nbsp;10<sup>9</sup>/L and absolute neutrophil counts [ANC] &ge;&nbsp;1&nbsp;&times;&nbsp;10<sup>9</sup>/L) and resolution of any extramedullary disease.</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp; </sup>CRi, per EAC, was defined as &lt;&nbsp;5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, incomplete recovery of peripheral blood counts (platelets &lt;&nbsp;100&nbsp;&times;&nbsp;10<sup>9</sup>/L and/or ANC &lt;&nbsp;1&nbsp;&times;&nbsp;10<sup>9</sup>/L) and resolution of any extramedullary disease.</p><p><sup>c&nbsp;&nbsp;&nbsp;&nbsp; </sup>1-sided p-value using Chi-squared test.</p><p><sup>d&nbsp;&nbsp;&nbsp;&nbsp; </sup>DoR, based on a later cutoff date than the CR/CRi, was defined for patients who achieved CR/CRi per Investigator&rsquo;s assessment as time since first response of CR<sup>a</sup> or CRi<sup>b</sup> per Investigator&rsquo;s assessment to the date of a PFS event or censoring date if no PFS event was documented.&nbsp;</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp; MRD-negativity was defined by flow cytometry as leukemic cells comprising &lt;&nbsp;1&nbsp;&times;&nbsp;10<sup>-4 </sup>(&lt;&nbsp;0.01%) of bone marrow nucleated cells.</p><p><sup>f&nbsp;&nbsp;&nbsp;&nbsp; </sup>Rate was defined as the number of patients who achieved MRD negativity divided by the total number of patients who achieved CR/CRi per EAC.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Among the initial 218 patients, as per EAC assessment, 32/109 patients (29%) in the BESPONSA arm achieved complete remission with partial hematologic recovery (CRh; defined as &lt;5% blasts in the bone marrow, ANC &gt; 0.5 x 10<sup>9</sup>/L, and platelet counts &gt; 50 x 10<sup>9</sup>/L but not meeting full recovery of peripheral blood counts) versus 6/109 patients (6%) in the Investigator&rsquo;s choice of chemotherapy arm, and 71/109 patients (65%) in the BESPONSA arm achieved CR/CRh versus 25/109 patients (23%) in the Investigator&rsquo;s choice of chemotherapy arm.</p><p>&nbsp;</p><p>Overall, 79/164 patients (48%) in the BESPONSA arm and 35/162 patients (22%) in the Investigator&rsquo;s choice of chemotherapy arm had a follow-up HSCT.</p><p>&nbsp;</p><p>Figure 1 shows the analysis of overall survival (OS). The analysis of OS did not meet the pre-specified boundary for statistical significance.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tromethamine (Trometamol) 10mg/vial, Sucrose 200mg/vial, Polysorbate 80 0.4mg/vial &amp; Sodium Chloride 2.4mg/vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life : 3 years


Instructions for Reconstitution, Dilution, and Administration

Protect the reconstituted and diluted BESPONSA solutions from light. Do not freeze the reconstituted or diluted solution. 

The maximum time from reconstitution through the end of administration should be less than or equal to 8 hours, with less than or equal to 4 hours between reconstitution and dilution. 

Reconstitution: 

•	BESPONSA is a cytotoxic drug. Follow applicable special handling and disposal procedures.1
•	Calculate the dose (mg) and number of vials of BESPONSA required. 
•	Reconstitute each vial with 4 mL of Sterile Water for Injection, USP, to obtain a concentration of 0.25 mg/mL of BESPONSA that delivers 3.6 mL (0.9 mg). 
•	Gently swirl the vial to aid dissolution. DO NOT SHAKE. 
•	Inspect the reconstituted solution for particulates and discoloration. The reconstituted solution should be clear to opalescent, colorless to slightly yellow, and essentially free of visible foreign matter. 
•	See Table 5 for storage times and conditions for the reconstituted solution.

Dilution: 

•	Calculate the required volume of the reconstituted solution needed to obtain the appropriate dose according to the patient’s body surface area. Withdraw this amount from the vial(s) using a syringe. Discard any unused reconstituted BESPONSA solution left in the vial.
•	Add reconstituted solution to an infusion container with 0.9% Sodium Chloride Injection, USP, to a make a total  volume of 50 mL. An infusion container made of polyvinyl chloride (PVC) (di(2 ethylhexyl)phthalate [DEHP]- or non-DEHP-containing), polyolefin (polypropylene and/or polyethylene), or ethylene vinyl acetate (EVA) is recommended.
•	Gently invert the infusion container to mix the diluted solution. DO NOT SHAKE. 
•	See Table 5 for storage times and conditions for the diluted solution. 

Administration:

•	See Table 5 for storage times and conditions for prior to and during administration of the diluted solution.
•	Filtration of the diluted solution is not required. However, if the diluted solution is filtered, polyethersulfone (PES)-, polyvinylidene fluoride (PVDF) ,or hydrophilic polysulfone (HPS) based filters are recommended. Do not use filters made of nylon or mixed cellulose ester (MCE). 
•	Infuse the diluted solution for 1 hour at a rate of 50 mL/h at room temperature (20 25°C; 68 77°F). Infusion lines made of PVC (DEHP  or non DEHP containing), polyolefin (polypropylene and/or polyethylene), or polybutadiene are recommended. 

Do not mix BESPONSA or administer as an infusion with other medicinal products. 

Table 5 shows the storage times and conditions for reconstitution, dilution, and administration of BESPONSA.

Table 5. 	Storage Times and Conditions for Reconstituted and Diluted BESPONSA Solution 
Maximum time from reconstitution through end of administration less than or equal to 8 hoursa

Reconstituted Solution	Diluted Solution
	After Start of Dilution	Administration
BESPONSA contains no bacteriostatic preservatives. Use reconstituted solution immediately or after being refrigerated (2 8°C; 36 46°F) for up to 4 hours. PROTECT FROM LIGHT. DO NOT FREEZE.	Use diluted solution immediately or after storage at room temperature (20 25°C; 68-77°F) for up to 4 hours or being refrigerated (2 8°C; 36 46°F) for up to 3 hours. PROTECT FROM LIGHT. DO NOT FREEZE.	If the diluted solution is refrigerated (2 8°C; 36 46°F), allow it to equilibrate at room temperature (20 25°C; 68 77°F) for approximately 1 hour prior to administration. Administer diluted solution within 8 hours of reconstitution as a 1 hour infusion at a rate of 50 mL/h at room temperature (20 25°C; 68 77°F). PROTECT FROM LIGHT.
a With less than or equal to 4 hours between reconstitution and dilution.


Protect the reconstituted and diluted BESPONSA solutions from light. Do not freeze the reconstituted or diluted solution.
The maximum time from reconstitution through the end of administration should be less than or equal to 8 hours, with less than or equal to 4 hours between reconstitution and dilution.

Do not use Besponsa after the expiry date which is stated on the Vial label after EXP:. The expiry date refers to the last day of that month.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Keep out of the sight and reach of children.</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>Refrigerate (2‑8&deg;C) BESPONSA vials and store in the original carton to protect from light. Do not freeze.</p><p>&nbsp;</p><p>BESPONSA is a cytotoxic drug. Follow applicable special handling and disposal procedures.<sup>1</sup></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BESPONSA (inotuzumab ozogamicin) for Injection is supplied as a white to off-white lyophilized powder in a single-dose amber Type I glass tubing vials with chlorobutyl lyophylization stoppers and crimp seals with flip-off caps for reconstitution and further dilution. Each vial delivers 0.9 mg inotuzumab ozogamicin. Each carton contains one single‑dose vial.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BESPONSA is a cytotoxic drug. Follow applicable special handling and disposal procedures.</p><p><em>&nbsp;</em></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Inc. USA
 
 
 

MANUFACUTRED BY

Wyeth Pharmaceutical Division of Wyeth Holdings LLC, a subsidiary of Pfizer Inc.

401 North Middletown Road, Pearl River, NY 10965, USA
 
 
 

PACKED & RELEASED BY

Pharmacia and Upjohn Company

7000 Portage Road, Kalamazoo, Michigan 49001, USA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>